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SUMMARY 
G protein-coupled receptors (GPCRs) are the largest family of proteins expressed 
in humans and are the target of over one-third of U.S. Food and Drug Administration 
(FDA) approved drugs.  Surprisingly, many GPCRs are “orphans” or lack endogenous 
ligands that prevent further study. Traditionally, GPCR-based assays used for drug 
discovery and deorphanization have relied on low-throughput methods and non-optimal 
assay hosts. Here, we present recent advances in GPCR-based assays and expand GPCR-
based assays in the yeast, Saccharomyces cerevisiae. 
In Chapter 1, we review the current state of the art of high-throughput GPCR-
based assays from the past two years. High-throughput screening (HTS) of GPCRs is used 
not only in pharmaceutical company drug discovery platforms, but is also regularly used 
to deorphanize, screen or repurpose other drugs, or look for off-target or potential side 
effects of therapeutics. There are multiple types of assays, such as: β-arrestin recruitment-
based, secondary messenger-based (i.e., cAMP, Ca2+, IP3, etc.), yeast-based, in vitro-based, 
and in silico-based assays. Multiple assays exist because there is no one perfect solution 
for the complexity seen in expression, G protein coupling, signaling, and regulation 
mechanisms in GPCRs. We highlight key advances in assay development and provide a 
future outlook on GPCR HTS.  
In Chapter 2, we develop an olfactory receptor- (OR-)based screening workflow 
in yeast, screen seven ORs against 57 chemicals and deorphanize two ORs for the first 
time. There are approximately 400 ORs expressed in humans and over 300 are still orphans. 
ORs are found ectopically throughout the body and have clinical impact. Of the nine highly 
 xvii 
expressed ORs of the human colon, only two are well studied and known endogenous 
ligands. To further understand ectopic ORs in the colon, we aimed to deorphanize the seven 
understudied receptors by rapidly creating sensors that coupled OR activation to green 
fluorescent protein (GFP) expression via the mating pathway in yeast and screening against 
odorants. Fluorescence microscopy revealed ORs were expressed in yeast and are 
trafficked to the membrane. Screening led to a total of six OR-chemical pairs that were 
validated by dose-response curves. This work will advance downstream effects of ectopic 
colon ORs by providing ligands to study receptor signaling. Additionally, this workflow 
can be applied to other GPCRs and chemical libraries to quickly identify ligands.  
In Chapter 3, we optimize the yeast-based sensor for the detection of serotonin 
with the serotonin receptor 4 (5-HTR4) and screen 1200 chemicals to find novel ligands. 
5-HTR4 is mainly expressed throughout the colon, where over 90% of serotonin is found, 
and is implicated in irritable bowel syndrome (IBS). We initially hypothesized that 
microbial metabolites could be interacting with 5-HTR4. To test this theory, we screened a 
natural products library against a yeast-based 5-HTR4 sensor. We engineered the sensor to 
improve speed and fold change by replacing GFP with NanoLuc luciferase.  Our initial hit 
was an anti-infective, which propelled the next screen of an anti-infective library. In total, 
we found three antimicrobial compounds that activated 5-HTR4 in our yeast-based assay 
and also promoted wound healing or proliferation in colon epithelium cells that 
endogenously express 5-HTR4. This work is intriguing as it may show that antimicrobials 
not only interact with microbes, but may influence the human host.  
 xviii 
Finally, Chapter 4 contains conclusions and future outlooks for yeast-based assays 
and Appendix A is a detailed method of how to perform the yeast-based serotonin receptor 
4 luciferase assay. 
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CHAPTER 1. ADVANCES IN HIGH-THROUGHPUT G 
PROTEIN-COUPLED RECEPTOR ASSAYS 
1.1 Abstract 
G protein-coupled receptors (GPCRs) are the largest family of human proteins and 
the target of over 30% of FDA approved drugs. High-throughput screening (HTS) of 
clinically relevant GPCRs is a first-line drug discovery effort in biomedical research. In 
this opinion, we review recent advances in GPCR HTS. Although our major focus is cell-
based assays, we also highlight recent advances in in vitro assays using purified receptors, 
and computational approaches for GPCR HTS. We conclude that as automation equipment 
becomes more widely available, GPCR HTS will begin to be used to probe basic biological 
process that will have an outsized impact on personalized medicine. Virtual docking now 
allows the screening of thousands of molecules in minutes, expediting the transition from 
drug candidate to pharmaceutical. However, reliance on the crystal structure of the target 
GPCRs limits the broad applicability of this strategy as only 65 of the 800 druggable 
GPCRs have structures. 
1.2 Introduction 
G protein-coupled receptors (GPCRs) are the largest family of human proteins and 
the target of over 30% of FDA approved drugs [1]. High-throughput screening (HTS) of 
clinically relevant GPCRs is a first-line drug discovery effort in biomedical research [2]. 
For example, Pfizer identified maraviroc as an agonist of chemokine receptor 5 (CCR5) 













uses for existing drugs. Raloxifene, an osteoporosis treatment, was identified to also be an 
inverse agonist of cannabinoid receptor 2 [4], an inflammation regulator. Prazosin, a 
hypertension treatment, was recognized to also be a partial agonist of CCR3 & CCR4, 
which are involved in autoimmune diseases and cancer metastasis [5]. About 100 non-
olfactory GPCRs remain orphan, i.e., there are no known ligands that activate them, thus 
their signaling pathways and ultimate phenotypes are unknown [6].  GPCR HTS was used 
to deorphanize GPR139 by screening ~200,000 chemicals to uncover LP-360924 as an 
Figure 1.1 Overview of HTS assays for GPCRs. 
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agonist [7].  Deorphanization of GPR139 has enabled understanding of its role in protecting 
dopaminergic neurons from degeneration [8], and is a drug target for Parkinson’s disease.  
The serendipitous expression of human GPCRs outside their endogenous tissue, 
together with the inefficient transduction of GPCR signaling in heterologous systems 
hinders the development of GPCR HTS.  Briefly, GPCR signaling consists of five steps: 
1) a “first messenger” binds a GPCR on the cell surface, 2) the activated GPCR couples to 
one of 18 different Gα proteins [9] or 4 β-arrestin [10], 3) Gα or β-arrestin amplify the signal 
by changing the concentration of a “second messenger” or by initiating a phosphorylation 
cascade, 4) the secondary messenger or terminal phosphorylated protein drives metabolic 
changes, and 5) the signal ends due to first messenger disappearance, GPCR 
desensitization, Gα deactivation, second messenger degradation, or terminal protein 
dephosphoarylation (Figure 1.1). 
Here, we review recent advances in GPCR HTS.  We classify GPCR assays based 
on the protein they coupled to and the different secondary messengers they activate.  
Although we focus on cell-based assays, we highlight advances in in vitro assays using 
purified receptors, and computational approaches for GPCR HTS.  Taken together, 
progress in GPCR HTS continues to reduce the time to arrive at a quality drug candidates.  
Novel computational approaches now allow the screening of thousands of molecules in 
silico, reducing the number of candidates that need to be tested experimentally.  
1.3 Cell-based GPCR high-throughput assays 
1.3.1 β-arrestin Recruitment-based Assays 
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Nearly all GPCRs will recruit β-arrestin to initiate receptor desensitization via 
internalization and some GPCRs recruit β-arrestin to initiate a mitogen-activated protein 
kinase (MAPK) pathway. In the Tango assay, a GPCR fused to a transcription factor via a 
TEV protease cleavage site recruits a β-arrestin linked to a TEV protease upon activation. 
This recruitment results in the release of the transcription factor and initiation of reporter 
gene transcription [11]. In 2015, Tango was expanded to more than 300 GPCRs by 
appending the C-terminus of the vasopressin receptor (“V2 tail”) to the C-terminus of 
GPCRs to generalize the recruitment of β-arrestin in PRESTO-Tango [12]. This system 
was used to screen 91 orphan GPCRs against 446 chemicals to successfully deorphanize 
two GPCRs: MRGPRX4, with the KATP-channel blocker nateglindide, and the BB3 
receptor, with the antiviral saquinavir [12]. In its most recent application, PRESTO-Tango 
was used to screen 320 non-olfactory receptors in parallel to identify selective agonists for 
the D2 dopamine receptor, a prominent neuropsychiatric drug target [13]. Although Tango 
has been primarily used as a high-throughput screen to identify GPCR agonists, antagonists 
can also be identified by running the assay in the presence of an agonist and measure the 
reduction in signal upon addition of potential antagonists. For example, the κ-opioid 
receptor antagonist ML350 was identified via HTS of over 16,000 chemicals by displacing 
the agonist U-50488 [14]. Κ-opioid receptor antagonists are used for the treatment of 
depression.  
In 2019, the screening reliability of Tango was improved in PiggyBac-Tango by 
integrating the GFP reporter and β-arresting constructs into the genome [15]. Using 
PiggyBac-Tango, the dopamine receptor 2, a target for psychiatric disorders and 
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Parkinson’s disease, was screened against 1,000 natural products and wilfortrine was 
identified as an agonist for the first time [15].  
Tango assays link one GPCR to one transcription factor to activate a single reporter 
gene.  To activate multiple genes, ChaCha replaces the transcription factor with a nuclease-
deactivated Cas9 and introduces multiple guide RNAs to activate multiple targets 
simultaneously [16]. ChaCha was used to activate the hM3D receptor to express both 
interleukin 2 (IL2) and interferon gamma (IFNG) and elicit an immune response. ChaCha 
is a great platform for comprehensively controlling metabolic fate, however, it has not yet 
been used for GPCR HTS applications. 
Reporters used in β-arrestin recruitment-based assays include luciferase, green 
fluorescent protein (GFP), split luciferase and beta-lactamase. Although luciferase allows 
the use of luminescence plate readers, it requires cell lysis of mammalian cells to achieve 
high signal-to-background ratio. GFP has a long maturation time and requires a high-
throughput cell imaging system for signal acquisition in mammalian cells. Split luciferase 
enables continuous monitoring of GPCR activation [17], but has yet to be used in GPCR 
HTS applications. In 2018, RNA barcodes read by RNA-seq were introduced as reporters 
[18]. Specifically, RNA barcodes allow cells expressing different GPCRs to be pooled and 
analyzed in parallel. In proof-of-principle work, nineteen aminergic receptors across five 
classes were assigned specific barcodes, pooled and tested against a mix of their five 
endogenous ligands. All receptors performed equally well in a pooled receptor and 
chemical environment. RNA barcodes should be used for GPCR HTS of large compound 
libraries for the identification of novel drugs in the future. 
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1.3.2 Secondary messenger-based assays 
GPCRs couple to four families of Gα subunits (Gαs, Gαi, Gαq and Gα12/13) with 18 
different isoforms that result in the upregulation of only a handful of secondary 
messengers. Gαs upregulates cAMP production, Gαi, inhibits cAMP production, Gαq, 
activates phospholipase C, which in turn produce diacylglyercol (DAG) and inositol 
triphosphate (IP3), the latter of which binds calcium channels, resulting in Ca2+ 
accumulation, and Gα12/13 increases RhoA activity. Here, we will highlight the most widely 
studied Gα subunits, Gαs, Gαi, Gαq, as direct measurement of Gα12/13 signaling is limited [19] 
due to cross-talk concerns because Gαq and Gβγ can also activate RhoA. 
1.3.3 cAMP-based assays 
 Detection of cAMP levels occurs via binding to the CREB transcription factor, 
which activates transcription of a reporter gene under control of the CRE promoter (pCRE). 
In 2019, the cAMP-based assay was used to screen β2-adrenergic receptor (β2AR) against 
~7,000 chemicals in neuroepithelial cells confirming that β2AR is activated by higenamine, 
a treatment for heart failure [20]. It is worth noting that GPCRs couple to different proteins 
depending on the ligand they bind, a concept termed biased signaling [21]. β2AR activates 
Gαs, Gαi or β-arrestin [22], thus a β2AR ligand identified via cAMP accumulation 
preferentially activates signaling via Gαs. To identify ligands that preferentially activate 
β2AR via β-arrestin or via Gαi, a Tango assay or a system that reports on the decrease in 
the cAMP concentration would be needed, respectively. RNA barcodes have also been 
used to increase the throughput of cAMP-based assays. Specifically, approximately 39 
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murine olfactory GPCRs were screened against 181 odorants in a pooled assay and 15 ORs 
were deorphanized [23]. 
In 2020, the Gαi coupled apelin receptor, a drug target for heart failure, was screened 
against a Bristol Myers Squibb proprietary library and was activated by aryl hydroxy 
pyrimidinone (AHPs) agonists [24]. AHPs are a new class of apelin agonists identified by 
HTS that can be used to treat heart failure. When testing a Gαi coupled GPCR, addition of 
an adenylate cyclase activator, such as forskolin, should be used to increase cAMP levels 
before adding a potential antagonist to measure reduction in cAMP or cAMP-dependent 
reporter gene transcription [25]. 
1.3.4 Calcium-based assays 
Activation of Gαq ultimately results in an increase in Ca2+ levels. Calcium dyes, such 
as Fluo-4, were the original choice to report on calcium fluctuation. However, their cost 
($25/96-well plate) and additional assay time (~1 hour) limited their use. In the early 2000s, 
genetically encoded calcium indicators (GECI) achieved similar affinity as synthetic dyes 
(~300 nM [26]) and improved fluorescence output [27] that made intracellular calcium 
detection widespread. 
In 2018, the genetically encoded Ca2+ and cAMP biosensors were introduced for GPCR 
HTS [28]. Briefly, a Nomad biosensor is attached to the plasma membrane and consists of 
a fluorescent protein link to a peptide that undergoes a conformational change upon 
chemical binding. Specifically, calmodulin-binding peptide (CaM) is used to bind Ca2+ and 
human thyroid A-kinase anchoring protein (HT31) is used to bind cAMP. Upon GPCR 
activation Ca2+ and cAMP can be detected by CaM and HT31, respectively, undergo a 
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conformational change resulting in increased fluorescence and vesicularization of the 
sensor, providing a phenotypic output seen as small green dots under the microscope when 
the cells are activated. Due to its mode of action, Nomad biosensors can detect multiple 
second messengers simultaneous, thus enabling the screening of chemicals for biased 
GPCR signaling. A multiplexed Nomad biosensor was used to screen the endothelin B 
receptor, a Gαs and Gαq coupled GPCR, against 1200 chemicals. This work elucidated three 
new ligands with the Ca2+ Nomad biosensor (Gαq signaling), and one of those ligands also 
was shown to activate cAMP Nomad (Gαs signaling). Taken together, the multiplexed 
Nomad biosensor has the potential to optimize the screening time of GPCRs with suspected 
biased signaling. Cytotoxicity of GECIs [29] results in reporter loss and reduced GECIs 
utility. By physically linking GECI to an antibiotic resistance marker using a self-cleaving 
peptide (GCaMP6s-2A-Bsr), loss of the GECI results in cell death, thus improving the 
GECI’s fluorescence intensity and long term expression stability [30]. GCaMP6s-2A-Bsr 
performed on par with Fluo-4 in a 384-well plate format using with the Gαq coupled 
muscarinic acetylcholine as a proof-of-principle GPCR.  
Before an increase in Ca2+ levels, Gαq activation results in an increase in DAG and IP3 
levels, which rapidly metabolizes into inositol diphosphate (IP2) and inositol 
monophosphate (IP1). In 2018, a commercial fluorescence resonance energy transfer 
(FRET)-based IP1 kit (IP-One) was used to screen STC-1 cells against casein hydrolysates 
and found LFC25 increases glucagon-like peptide 1 (GLP-1) production [31]. While not 
directly measuring one GPCR signal transduction, GLP-1 secretion is modulated by 
multiple Gαq GPCRs. Several DAG fluorescent protein-based sensors are available, but 
high resolution microscopy is needed, thus limiting its throughput [32]. In 2016, a DAG 
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FP-sensor was optimized by testing brighter GFP variants for potential use in HTS [33] 
and is commercially available (DAG Assay Kit). To our knowledge, the DAG FP-based 
sensor has not been used in HTS of a Gαq coupled GPCR. 
1.4 Saccharomyces cerevisiae as a heterologous host 
Mammalian cells express tens of GPCRs on the cell surface (e.g., 75 in HEK293 [34]), 
changing the concentration of only a handful of second messengers. Thus, changes in 
reporter gene expression may not be necessarily due to activation of the desired receptor, 
but activation of a different receptor that results in the measured output. The yeast 
Saccharomyces cerevisiae with only two GPCRs on its cell surface is the ideal host to 
screen human GPCR activation. Briefly, S. cerevisiae expresses only the pheromone 
(Ste2/Ste3) and a glucose sensing (GPR1) GPCR [35], has no β-arrestins, and GPCR 
transduction occurs via two Gαs, GPA1 and GPA2, which activate either a MAPK pathway 
or cAMP cascade, respectively [36]. 
In 2017, the first β-arrestin-based assay was performed in S. cerevisiae by fusing the 
somatostatin receptor 2 (SSTR2) and human β-arrestin to complementary fragments of 
luciferase [37]. The assay was validated using two known agonist, assay signal was optimal 
after 60 minutes, albeit it only had a three-fold increase in signal after activation. A 
drawback of β-arrestin-based assays in yeast is the lack of GPCR kinases often needed to 
phosphorylate the GPCR for β-arrestin recruitment [38]. Although SSTR2 did not need 
phosphorylation [37], to expand β-arrestin-based assays in yeast, GPCR kinases will need 
to be co-expressed. 
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Human GPCRs can couple to GPA1 or GPA1/human Gα chimeras [39] to hijack and 
activate the mating pathway to report on GPCR activation. To do this, deletion of the 
pheromone receptor (ste2), along with far1 and sst2 that prevents cell cycle arrest and Gα 
desensitization, respectively, is needed. Leftkowitz et al. [40] originally introduced this 
strategy in 1990 by coupling β2AR to the yeast MAPK pathway. Of note, yeast GPCR HTS 
allows use of growth as the reporter, opening the door to screening 106-108 compounds 
against one GPCR or 106-108 GPCR mutants against one chemical every three days. This 
throughput has been used to engineer GPCRs exclusively activated by inert drugs, a widely 
used chemogenetic tool in neuroscience [41]. 
Yeast-based GPCR HTS have been used for drug discovery.  In 2015, GPR68, a proton-
sensing GPCR involved in asthma, was screened against 446 chemicals using a liquid 
growth assay read every three days in 96-well plates [42]. Lorazepam, an anti-anxiety 
medication, was identified as a GPR68 allosteric agonist as it was modulated by pH. 
Lorazepam was then used to probe GPR68 downstream signaling pathways. To increase 
the throughput, the luciferase receptor was introduced for GPCR HTS for drug discovery.  
In 2019, the serotonin 4 receptor (5-HTR4) was screened against 1,200 natural products 
and anti-infection compounds where antimicrobials were identified as 5-HTR4 agonists for 
the first time [43]. The total assay time was 2.5 hours, which can be performed in parallel, 
and using a 96-well plate luminescence plate reader the chemical evaluation throughput 
was one compound per second. The assay used GPA1 to couple to the mating pathway, 
which is a good mimic for human Gαs, which 5-HTR4 couples to, however, GPA1 may not 
be a good substitute for other Gαs [44]. 
 11 
In addition to non-sensory GPCRs, olfactory receptors (ORs) have been coupled to the 
yeast mating pathway [45]. In 2019, seven ORs were screened against 57 chemicals 
resulting in the deorphanization of two ORs [46]. The assay linked OR activation to GFP 
expression, which takes four hours to achieve robust GFP signal. The assay is read using a 
HT-flow cytometer at a throughput of one 96-well plate per hour. 
1.5 In vitro GPCR high-throughput assays 
The low stability of purified GPCRs makes their screening outside cells or membrane 
systems challenging. Advances in engineering GPCRs for protein stability [47] have 
increased the number of in vitro GPCR assays. Radioligand binding assays are still used as 
a sensitive assay to determine GPCR cell surface expression/internalization [48] and ligand 
binding [49]. However, fluorescence-based techniques along with affinity-based screens 
are becoming more popular due to the lack of radioactivity and increased throughput.  
Fluorescence polarization can distinguish an unbound fluorescently labelled ligand 
from a receptor-ligand pair by the difference in the molecular tumbling speed. A key 
challenge with this technique is the availability of fluorescently-labelled substrates. In 
2019, neurotensin receptor type 1 (NTS1) with improved stability was used to develop a 
high-throughput competitive binding assay using a commercially available fluorescently-
labeled NTS1 peptide ligand [50]. In a 384-well plate format, the displacement of 
fluorescently-labeled NTS1 peptide ligand was used to screen over 1,200 chemicals in just 
one hour of incubation. Surface plasmon resonance (SPR) confirmed 8 of the 15 identified 
hits.  
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Affinity MS is an enrichment method that can isolate and identify GPCR ligands from 
a pool [51].  In 2019, an adenosine receptor (A2AR) with improved stability [52] was 
purified and screened against 20,000 chemicals. First, A2AR was mixed with the chemical 
library and the unbound chemicals were washed. Next, the receptor was denatured, the 
chemicals recovered, and incubated with freshly prepared A2AR. Nine new A2AR ligands 
were validated using SPR.  Affinity MS can also be applied to membrane systems, albeit 
they have a higher signal to background ratio than purified enzymes.  While affinity mass 
spectrometry is a sensitive technique, however the requirement of purified enzyme limits 
it to highly stable GPCRs. 
1.6 In silico GPCR-based high-throughput assays 
With a seemingly endless chemical space to identify GPCR ligands, computational and 
bioinformatics methods effectively reduce the number of ligand candidates that need to be 
evaluated experimentally.   
Bioinformatic techniques, including sequence alignment, evolutionary trace analysis, 
and principal component analysis, were used to guide a deorphanization attempt of putative 
peptide orphan GPCRs leading to the pairing of five receptors with multiple endogenous 
peptide ligands in 2019 [53]. Key features in peptide GPCRs were identified to narrow the 
GPCR space to down 21 putative peptide receptors. To reduce the ligand space, secreted 
proteins were mined from the human proteome to reach 1,227 potential peptide candidates 
and using machine learning they were focused to 131 peptide candidates. As the 
downstream signaling pathway for orphan receptors are not known, to screen the 131 
peptides against 21 receptors, three nonspecific G-protein signaling assays were used: mass 
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redistribution, receptor internalization (time-resolved-FRET), and β-arrestin recruitment 
(Tango). Given that computational approaches significantly reduce the number of GPCR-
ligand hits to be validated, real-time lower-throughput approaches, such as mass 
distribution and receptor internalization, can be used. 
Computational docking methods (e.g., Dock3.7 [54]) using ultra-large chemical 
libraries expand chemical library diversity and size from thousands, e.g., human proteome 
~20,000 to hundreds of millions, e.g., potential small molecule drug candidates 1063 [55]. 
In 2019, 138 million chemicals were virtually screened against the dopamine 4 receptor 
(D4), the pharmacological target for schizophrenia and Parkinson’s disease, in a single day 
[56]. The top 549 computationally generated chemical hits were chemically synthesized, 
and a radioactivity assay was used to validate 22% of the hits. Additionally, 81 chemicals 
showed Kis in low the nM to µM range indicating virtual docking was successful in 
narrowing down millions to a couple of hundred leads to validate experimentally. In 2020, 
over 150 million chemicals were virtually screened against melatonin receptor 1 (MT1) 
[57]. After manual inspection of top scoring results, 40 chemicals were synthesized 15 of 
which showed activity for either melatonin receptor 1 or 2 (61% similar) using Tango and 
cAMP assays. Of note, the authors identified four new specific agonists for MT1 without 
the need to search analogous structures further. Online chemical databases that are 
compatible with virtual screening (e.g., ZINC [58], ChEMBL [59]) have expanded 
diversity by increasing the sheer scale of chemical testing and by allowing the frequent 
incorporation of new scaffolds [56]. Use of these ultra-large chemical libraries for virtual 
docking are most effective when crystal structures are available [60].  Homology modeling 
and sequence alignment are not useful when only 64 unique GPCR structures are known 
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[61]. This is a setback in virtual docking, as 85% of non-olfactory GPCRs, and all olfactory 
GPCRs, do not have structures.      
1.7 Future Outlook 
To identify new ligands for GPCRs, there is not a single go-to assay. GPCRs couple 
through four different Gα subunits in addition to β-arrestin, thus the GPCR HTS chosen 
needs to take into account the identity of the GPCR as well as the protein it couples for 
signal transduction. GPCR HTS are robust and have led to the identification of new drugs, 
the repurposing of existing drugs, and more recently the identification of chemicals with a 
G-protein transduction bias. With the wider availability of automation equipment together 
with more user-friendly computational platforms, we are at an apogee of GPCR HTS. 
To date, GPCR HTS applications have focused on drug discovery. However, as 
automation equipment becomes more common in academic laboratories, we foresee GPCR 
HTS being used to question and probe basic biological processes. For example, different 
GPCR isoforms tend to be expressed in different cell types. By applying GPCR HTS, we 
can start to elucidate the extent different cell types are activated by different ligands. 
Further, different patient populations tend to have different GPCR alleles, and GPCR HTS 
could help elucidate the extent to which different GPCR alleles are activated. With the 
potential of having each patient’s genome sequenced in the near future, we can envision 
GPCR HTS of chemical and peptide libraries to be a common occurrence to generate 
lifesaving therapies.   
Bioinformatics and virtual docking presents another unique way for the field to rapidly 
deorphanize GPCRs or find potential drugs. However, there is a higher success rate when 
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the docking analysis is done in the specific GPCR structure and not a homolog thereof. 
With 64 unique GPCR structures and a total of 800 druggable GPCRs, we have some way 
to go to apply virtual docking strategies to all GPCRs. To date, machine learning has been 
used to reduce the chemicals search space. In the future, machine learning promises to 
provide an avenue to combine bioinformatics, experimental and docking data to predict 
potential GPCR ligands and even deorphanize GPCRs in the future. 
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2.1 Abstract 
 Olfactory receptors are ectopically expressed (exORs) in more than 16 different 
tissues. Studying the role of exORs is hindered by the lack of known ligands that activate 
these receptors. Of particular interest are exORs in the colon, the section of the 
gastrointestinal tract with the greatest diversity of microbiota where ORs may be 
participating in host−microbiome communication. Here, we leverage a G-protein-coupled 
receptor (GPCR)-based yeast sensor strain to generate sensors for seven ORs highly 
expressed in the colon. We screen the seven colon ORs against 57 chemicals likely to bind 
ORs in olfactory tissue. We successfully deorphanize two colon exORs for the first time, 
OR2T4 and OR10S1, and find alternative ligands for OR2A7. The same OR 
deorphanization workflow can be applied to the deorphanization of other ORs and GPCRs 
in general. Identification of ligands for OR2T4, OR10S1, and OR2A7 will enable the study 
of these ORs in the colon. Additionally, the colon OR-based sensors will enable the 
elucidation of endogenous colon metabolites that activate these receptors. Finally, 
deorphanization of OR2T4 and OR10S1 supports studies of the neuroscience of olfaction. 
2.2 Introduction  
Olfactory receptors (ORs) make up the largest group of G-protein-coupled receptors 
(GPCRs) and are used by organisms to sense their chemical environment.1 Rather than 
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binding a single chemical, ORs bind a range of chemicals with different affinities.2 
Identification of ligands that activate orphan ORs remains a challenging process.3 To date, 
only 10% of the approximately 400 human ORs have known ligands.3,4 Both experimental 
and computational approaches have been applied to OR deorphanization. Among the most 
large-scale ones is the use of a mammalian-based OR assay to screen 394 human ORs 
against 73 chemicals to deorphanize 18 ORs.5,6 Computational approaches have been used 
to generate machine learning algorithms by virtually screening hundreds of chemicals 
against ORs with known ligands, yet the algorithms have failed to deorphanize ORs.7 
More than 20% of the human ORs are also expressed ectopically outside the olfactory 
tissue,8,9 and their function in these tissues is just starting to be elucidated. OR1D2 
expression in the testis has been implicated in chemotaxis;10 OR51E2 expression in the 
kidney mediates renin secretion,11 and OR151E1 and OR51E2 in the colon respond to 
short-chain fatty acids11−14 likely produced by gut microbiota leading to changes in gene 
expression.13 The key to studying the role of ectopically expressed ORs (exORs) and the 
identification of endogenous ligands present in the tissues in which they are expressed is 
the availability of “synthetic ligands” that activate these receptors in the laboratory. To 
date, nine of the 84 ectopically expressed human ORs have known ligands.10−18 In the 
human colon, nine ORs are expressed with high confidence: OR10S1, OR2A7, OR2A42, 
OR2L13, OR2T4, OR2W3, OR51B5, OR51E1, and OR51E2.9 The role of OR51E214 and 
OR51E119 in the colon has been well studied. Synthetic ligands for OR51B5 (isononyl 
alcohol17), OR2A7 (cyclohexyl salicylate20), and OR2W3 (nerol18) have been reported. 
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The other four ORs (OR10S1, OR2A42, OR2L13, and OR2T4) remain orphans. 
Deorphanization of these four ORs and finding alternative ligands for OR51B5, OR2A7, 
and OR2W3 would help to elucidate the role of ORs in the colon. Additionally, 
Figure 2.1 – Ectopically expressed olfactory receptor (exOR) sensors and the 
chemical panel. (A) OR deorphanization workflow. (B) Yeast-based OR sensor. OR 
(blue) is expressed in a yeast sensor strain that links receptor activation to green 
fluorescent protein (GFP). (C) Principal component analysis of the 57-member 
chemical panel. Chemical Spaces (CS): CS1, red dot; CS2, green dot; CS3, blue dot; 
CS4, orange dot; CS5, purple square; CS6, light blue square; CS7, pink dot; CS8, 
black square. (D) Localization of human ORs when expressed in yeast.  
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deorphanization of OR10S1, OR2A42, OR2L13, and OR2T4 would aid in the studies of 
the neuroscience of olfaction. 
Here, we develop a workflow for the rapid deorphanization of olfactory receptors 
and apply it to the deorphanization of human ORs expressed in the colon (Figure 2.1). 
Specifically, we leverage a previously engineered GPCR-based yeast sensor strain21 
(Figure 2.1) to generate seven colon exOR sensors. We screen each of these colon ORs 
against a 57-member chemical panel to successfully deorphanize two receptors, OR2T4 
and OR10S1, and identify two alternative ligands for OR2A7. The OR deorphanization 
workflow can be readily applied to the deorphanization of other ORs. The yeast-based OR 
assay is faster than its mammalian cell counterpart due to the shortened doubling time and 
nonrequirement of cell passage. In addition, yeast-based OR sensors can be stored for up 
to a month at 4 °C before use. The newly identified ligands for OR2T4, OR10S1, and 
OR2A7 now allow for the elucidation of the role of these ORs in the colon. The OR high-
throughput screening assay enables the elucidation of endogenous OR ligands in the colon. 
2.3 Materials and Methods 
2.3.1 Materials 
Tert-butylbenzene (B90602) and 3-phenylbutyraldehyde (289027) were purchased from 
Sigma-Aldrich. Nonanoic acid (N0288) and nerol (N0077) were purchased from TCI 
Chemicals. Supplier information for the chemical panels can be found in Table F.1. 
2.3.2 Principal Component Analysis for the Chemical Panel.  
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Simplified molecular-input line-entry system (SMILES) codes for the 57 chemicals in the 
panel were obtained from PubChem and used as inputs to Instant JChem (ChemAxon) to 
acquire information about 23 descriptors. Eight descriptors were chemical functional 
groups, and 15 descriptors were from a method by Wenderski et al.22 The principal 
components (PCs) were calculated using Solo Eigenvector (Eigenvector Research). Three 
PCs, which encompass 63% cumulative variance, were selected by evaluating eigenvalues. 
PC scores exported from Solo were used to create scatter plots in MATLAB. 
2.3.3 Strains and Plasmids. 
 Human olfactory receptors OR2A4, OR2W3, OR2T4, OR51B5, OR2L13, 
OR10S1, and OR2A7 were codon-optimized for Saccharomyces cerevisiae and 
commercially synthesized. ORs were cloned into pKM111 at BamHI/SacII sites via Gibson 
assembly to create pHW3, pHW6, pHW7, pHW18, pPB8, pHW20, and pHW21, 
respectively. The sequences of the plasmids were verified using primers EY46 and HW12. 
To construct the OR-based sensors, pHW3, pHW6, pHW7, pHW18, pPB8, pHW20, or 
pHW21 was co-transformed with pRS415-PFIG1-eGFP-Leu2 (pKM586) into yeast sensor 
strain PPY14021 (W303 Δfar1, Δste2, Δsst2) to generate PPY1801−1807. To construct the 
control strain lacking the OR, PPY140 was co-transformed with pKM586 and an empty 
vector to generate PPY1800. 
 To construct OR-GFP fusion plasmids, ORs were amplified from pHW3, pHW6, 
pHW7, pHW18, pPB8, pHW20, and pHW21 using primer HW1 with HW4, HW7, HW8, 
HW9, PB89, PB116, and PB118, respectively. GFP was amplified from pKM586 using 
primer HW12 with overlap to ORs with HW15, HW18, HW19, HW20, PB88, PB115, and 
PB117. ORs and GFP were cloned into pKM111 at BamHI/SacII sites via Gibson assembly 
to create pHW22, pHW23, pHW30, pHW33, pPB59, pPB60, and pPB54, respectively. 
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2.3.4 OR Fluorescence Microscopy. 
Overnight cultures of PPY1949−PPY1955 were used to inoculate 20 mL of SD(H−) until 
an OD600 of 0.06 was reached. After 18 h at 15 °C (150 rpm), cultures were spun down at 
3500 rpm for 10 min and resuspended in 200 μL of SD(H−). One drop (2 μL) of Calcofluor 
White Stain (Sigma-Aldrich) and one drop (2 μL) of 10% potassium hydroxide were added 
to the specimen (2 μL) directly on the slide. Yeast was visualized on a Zeiss LSM 700 
confocal microscope using the 63× objective lens. GFP was excited using the 488 nm laser 
line, and Calcofluor white was excited using the 405 nm line.  
2.3.5 Screening ORs with a 57-Member Chemical Panel. 
Overnight cultures of PPY1801−PPY1807 were used to inoculate 20−40 mL of synthetic 
complete medium with 2% glucose lacking histidine and leucine [SD(HL−)] until an OD600 
of 0.06 was reached. After 18 h at 15 °C (150 rpm), cultures were spun down at 3500 rpm 
for 10 min and resuspended to an OD600 of ≈1 (1/10th of the culture volume). In a 96-well 
plate, 190 μL of fresh SD(HL−), 8 μL of the cell suspension, and 2 μL of the solution of the 
chemical [final chemical concentration of 10 μM, 1% dimethyl sulfoxide (DMSO)] were 
added. After incubation (4 h, plates covered with Breathe Easy Sealing Membrane, 30 °C, 
250 rpm), the GFP fluorescence was read using a Millipore Guava easyCyte HT flow 
cytometer (λex = 488 nm; flow rate of 1.18 μL/s). Samples were run in triplicate. Data from 
5000 cells were collected, and 70−95% of viable cells were gated using FlowJo. The 
geometric mean of the mean fluorescence of the gated cells was used to calculate in 
Microsoft Excel p values using a Student’s t test with two tails using equal variance to 
define chemical hits (p < 0.05).  
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2.3.6 OR/Chemical Dose-Response Curves. 
The same protocol for OR chemical screening was followed. To a test tube were added 4.8 
mL of SD(HL−), 200 μL of the cell suspension, and 50 μL of the chemical (final chemical 
concentrations of 0−1000 μM, 1% DMSO). After incubation (4 h, plates covered with 
Breathe Easy Sealing Membrane, 30 °C, 250 rpm), the GFP fluorescence was read using a 
BD LSR II flow cytometer (488 nm laser line; 515−545 nm filter; FSC, 150 V; SSC, 200 
V; FITC, 450 V; FSC threshold, 5000). Samples were run in triplicate. Data from 10000 
cells and 70−95% of viable cells were gated using FlowJo. The geometric mean of the 
mean fluorescence of the gated cells was plotted in OriginPro 2016. Statistically significant 
points were calculated using Microsoft Excel Student’s t test with two tails using equal 
variance. To compare different conditions in a single plot (Figure 2.5 and Figure 2.10), the 
percent GFP expression was calculated using the formula below. First, the percent GFP 
expression of every data point for each condition was calculated taking into account GFP 
(AU) for all conditions to be plotted in the same graph. Then, the percent GFP expression 
was averaged and the standard deviation calculated. 
% GFP expression = 100[(GFPsample − GFPmin)/ (GFPmax − GFPmin)] 
To calculate EC50s, the data in Figure 2.5 and Figure 2.10 were fitted to a dose-response 
equation in OriginPro 2016 using the following formula. 




2.3.7 Chemical toxicity to yeast-based OR sensor.  
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Overnight cultures of PPY1802, PPY1804, PPY1806, and PPY1807 where diluted to an 
OD600= 1 in 5 mL of SD(HL- ). Cultures were incubated for 4 hours at 30°C, 250 rpm 
with varying chemical concentrations with a final DMSO concentration of 1%. OD600 was 
measured after incubation. The experiments were run in triplicate. 
2.3.8 mRNA Quantification  
Following the OR biosensing protocol, between 2 x 107 and 5 x 107 cells were pelleted 
and total RNA was extracted using Qiagen RNeasy Mini Kit. RNA concentration was 
measured using a Nanodrop Lite spectrophotometer and stored at -80°C. Reverse 
transcription was executed using 700 µg of total RNA using the QuantiTect Reverse 
Transcription kit (Qiagen). Quantitative PCR reactions were set up using the QuantiTect 
SYBR Green PCR kit (Qiagen) using cDNA from 42 ng of mRNA and read using a 
StepOnePlus Real-Time PCR system (Applied Biosciences). Reactions were set up as 
technical triplicates using primers EY270/EY271 for OR10S1, EY272/EY273 for OR2A7, 
EY274/EY275 for OR2T4, and ACT-F/ACT-R for actin. OR expression were normalized 
to the housekeeping gene, ACT1, that encodes actin and relative expression of chemical 
versus no chemical (DMSO) was compared using the comparative CT method (Livek and 
Schmittgen, 2001) using the equations below. 
∆𝐶'_)*+,-.	 =	𝑎𝑣𝑔𝐶'_)*+,-. − 𝑎𝑣𝑔𝐶'_!0123 
∆∆𝐶' =	∆𝐶'	 −	∆𝐶'_45)6	 
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= 𝑀𝑒𝑎𝑛	𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒	𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛	𝑜𝑓	𝑔𝑒𝑛𝑒	𝑜𝑓	𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡	𝑐𝑜𝑚𝑝𝑎𝑟𝑒𝑑	𝑡𝑜	𝐷𝑀𝑆𝑂	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
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2.4 Results and Discussion 
2.4.1 Structural Diversity in the 57-Member Chemical Panel. 
ORs account for 3% of all coding genes in humans23 and bind a variety of chemicals 
from terpenes and esters to acids and aldehydes. To identify ligands that activate the seven 
ORs, we screened them against 57 chemicals likely to bind ORs in olfactory tissue. To 
understand the structural diversity of the 57 chemicals, each chemical was broken down 
into 23 descriptors to perform a principal component analysis (Figure 2.1). The top three 
principal components (PCs) account for 63% of the cumulative variance. On the basis of 
their PC scores, chemicals can be separated into eight chemical spaces (CSs): CS1, cyclic 
compounds; CS2, medium-chain esters, alcohols, and aldehydes; CS3, aromatic 
compounds; CS4, long-chain esters; CS5, heptatonic acid and geraniol; CS6, short-chain 
hydrocarbons with oxygen-containing functional groups; CS7, long-chain acids; CS8, 
chemicals with at least two oxygen-containing functional groups. The most well 
represented chemical space is CS6, accounting for 23% of the chemicals in the panel. 
 
Figure 2.2 Dose-response curve of OR2W3 with nerol. 
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2.4.2 Colon OR Sensor Generation. 
We codon-optimized OR10S1, OR2A7, OR2L13, OR2T4, OR51B5, OR2A42, and 
OR2W3 for expression in the yeast S. cerevisiae and commercially synthesized them. We 
cloned the ORs under a strong promoter in a high-copy number plasmid and transformed 
them in the GPCR yeast sensor strain21 to generate the seven colon OR-based sensors. 
Incubation of OR2W3 with nerol did not result in a significant increase in the signal after 
activation (Figure 2.2). ORs sometimes bind different ligands depending on the Gα subunit  
Table 2.1 – Sequence identity of ectopically expressed olfactory receptors in the colon 
  OR2A7 OR2T4 OR2A42 OR2W3 OR51B5 OR2L13 OR10S1 
OR2A7               
OR2T4 39.90%             
OR2A42 71.30% 44.00%           
OR2W3 42.70% 41.60% 46.90%         
OR51B5 31.80% 28.80% 32.20% 27.60%       
OR2L13 39.50% 49.20% 42.20% 39.30% 26.20%     
OR10S1 39.60% 36.40% 41.70% 41.60% 28.20% 40.30%   
to which they are coupling.24,25 Sometimes, an OR is activated by the same ligand 
independent of the Gα subunit to which it is coupled, and when it is coupled to Golf, a signal 
enhancement in observed.26,27 Nerol was discovered as a ligand for OR2W3 using Golf.18 In 
the yeast system, the ORs couple to the native yeast Gα subunit GPA1. It is possible that 
nerol does not efficiently activate OR2W3 when coupling to GPA1. Cyclohexyl salicylate 
($400/mg) and isononyl alcohol ($600/mg) were not readily available and too expensive 
to be used as synthetic ligands for OR2A7 and OR51B5, respectively. Thus, we set out to 
identify ligands for all seven ORs. The seven ORs do not have a high degree of sequence 
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identity with the closest sequences being OR2A7 and OR2A42 (71.3%) and the most 
distant sequences being OR51B5 and OR2L13 (26.2%) (Table 2.1).  
Figure 2.3 - Rapid deorphanization of human olfactory receptors (ORs). (A) Heat 
map of P values of chemicals leading to a statistically significant increase in the level 
of GFP expression when compared to the dimethyl sulfoxide (DMSO) control (P < 
0.05). (B) Dose-response curves of ORs with 23 chemical hits. Blue curves are for 
chemicals leading to a statistically significant increase in the intensity of the signal 
after activation. Red curves are for chemicals resulting in a >2-fold increase in the 
intensity of the signal after activation. Asterisks denote statistically significant 
increases (P < 0.05) in the intensity of the signal after activation when compared to no 
chemical. 
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2.4.3 Verification of Colon OR Expression in Yeast. 
To verify the yeast expression of the seven human ORs, we fused green fluorescent 
protein (GFP) to the C-terminus of the ORs. The seven ORs are expressed in yeast and 
could be found at the cell membrane (Figure 2.1). The OR expression pattern was 
sequence-dependent. While OR2A42 was mostly localized to the cell membrane, OR10S1 
was expressed throughout yeast. OR2T4 and OR2W3 showed a punctuated pattern, i.e., 
the ORs had challenges translocating to the membrane, likely accumulating in the 
 
Figure 2.4 – Dose-response curves of the nine OR/chemical pairs that did not result 
in a statistically larger increase in the intensity of the signal after activation. All 
measurements were carried out in triplicate, and means ± the standard deviation are 
shown. 
endoplasmic reticulum. Of note, the OR sensor strain amplifies the chemical signal 
detected by the OR; i.e., activation of the OR leads to the activation of a large number of 
transcription factors that go on to activate GFP expression. Thus, it is not necessary to have 
a large number of ORs on the cell surface to detect GFP expression. 
2.4.4 Rapid Screening of Colon ORs against the 57-Member Chemical Panel. 
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Each OR was screened in triplicate against 57 chemicals and DMSO as a control. 
Chemicals resulting in a statistically significantly increase in the level of GFP expression 
(p < 0.05) when compared to the DMSO control were considered hits (Figure 2.3). There 
were a total of 32 chemical hits. OR10S1 had the largest number of hits (10). OR2T4 and 
OR2A7 had five hits each. OR2A42 had the fewest number of chemical hits (two).  
2.4.5 Secondary Screening of OR Chemical Hits. 
 To validate the chemical hits from the rapid screening stage, we determined dose-
response curves of the OR/chemical hit pairs (Figure 2.3 and Figure 2.4). Chemical hits 
were validated if at any of the concentrations tested in the dose-response curve there was a 
statistically significant increase in the signal after activation when compared to the DMSO 
control. In the case of OR10S1, seven of 10 chemical hits were validated, with lilial and 
nonanal leading to a >2-fold increase in the signal after activation. All five OR2T4 
chemical hits were validated, with α-pinene, farnesol, lilial, and undecanal showing a >2-
fold increase in the signal. The two OR2A42 chemical hits were validated, with farnesol 
resulting in a 2-fold increase in the signal after activation. Four of the five OR2A7 chemical 
hits were validated, with α-pinene and lilial leading to a >2-fold increase in the signal after 
activation. In the case of OR2L13, three of the four chemical hits were validated, with 
dodecanol and undecanal resulting in a >2-fold increase in the signal. Two of the three 
OR51B5 chemical hits were validated with dodecanoic and farnesol leading to a >2-fold 
increase in the signal after activation. None of the three OR2W3 chemical hits were 
validated. Taken together, we validated at least one hit for each OR except for OR2W3. 
We find multiple hits for some ORs, which is consistent with olfactory receptors’ tendency 
to bind a family of chemicals.  
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2.4.6 Confirming OR-Dependent GFP Expression. 
 
Figure 2.5 – Confirming OR-dependent activation with validated chemicals. Dose-
response curves of validated chemicals in the presence (solid lines) and absence 
(dotted lines) of ORs: (A) OR2A7 and OR2T4 with α-pinene, (B) OR2A7, OR2T4, 
and OR10S1 with lilial, (C) OR51B5, OR2T4, and OR2A42 with farnesol, and (D) 
OR2T4 and OR10S1 with undecanal and nonanal, respectively. All measurements 
were carried out in triplicate, and means ± the standard deviation are shown. 
 
Figure 2.6  – Dose-response curves of three OR/chemical pairs that do not show OR-
dependent GFP expression. Dose-response curves of OR2L13 and OR51B5 with 
validated chemicals. A. OR2L13 with dodecanol. B. OR2L13 with undecanal. C. 
OR51B5 with dodecanoic acid. 
To confirm that the validated chemicals lead to cell fluorescence via OR activation 
and not an alternative mechanism, we determined dose-response curves of the validated 
chemicals with a control strain carrying an empty vector in place of the OR and the GFP 
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reporter plasmid (Figure 2.5 and Figure 2.6). We focused on OR/ chemical pairs resulting 
in a ≥2-fold increase in the signal after activation: pinene with OR2A7 and OR2T4; lilial 
with OR2A7, OR2T4, and OR10S1; farnesol with OR51B5, OR2T4, and OR2A52; 
nonanal with OR10S1; and undecanal with OR2T4. The chemicals inhibit cell growth, but 
the cells remain at the same optical density as at the start of the experiment (Figure 2.7). 
We fitted the OR/chemical pair data to a dose-response equation to calculate EC50s. To 
reliably compare the responses of the chemicals, we ran OR and no OR control experiments 
pairwise on the same day.  
 
Figure 2.7 – Chemical toxicity to yeast-based OR sensor. Yeast cell density was 
measured after the 4-hour incubation step in the OR chemical sensing protocol. The 
no chemical data point has 1% DMSO. While the yeast cells double in the absence of 
chemical, their cell density is static in the presence of chemical. 
Pinene elicits basal GFP expression in the absence of a receptor (Figure 2.5A). In 
the presence of pinene, the OR2A7 EC50 is 412 μM while the OR2T4 EC50 is 659 μM. In 
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the presence of OR2T4, pinene addition results in a 3-fold increase in GFP expression 
when compared to the no receptor control. In contrast, in the presence of OR2A7, pinene 
addition results in an only 2.3-fold increase in percent GFP expression when compared to 
the no receptor control. The maximal level of GFP expression of OR2T4 is 63% higher 
than that of OR2A7.  
Lilial elicits a basal GFP expression that is comparable to that of pinene (Figure 
2.5B). The EC50s of OR2A7 and OR2T4 with lilial are almost indistinguishable at 110 and 
107 μM, respectively. Lilial shows a lower chemical potency with OR10S1 with an EC50 
of 129 μM. Lilial elicits GFP expression with OR10S1, resulting in a 3.8-fold increase in 
percent GFP expression when compared to the no receptor control.  
Farnesol results in a basal GFP expression that is comparable to that seen with 
pinene and lilial (Figure 2.5C). The farnesol response obtained in the presence of OR2T4 
and OR2A42 could not be fitted to a dose-response equation with the curves resembling 
an on/off response. The response of OR51B5 to farnesol could be fitted to a dose-response 
curve, resulting in an EC50 of 181 μM, and it has a 3-fold increase in percent GFP 
expression compared to the no receptor control.  
The two aldehydes, undecanal and nonanal, elicit a slightly higher basal GFP 
expression than pinene, lilial, or farnesol (Figure 2.5D). Although OR10S1 shows an 
increase in its signal after activation upon nonanal addition, the no OR control shows a 
similar increase in GFP expression. In the presence of OR2T4, the addition of undecanal 




Figure 2.8 – Changes in olfactory receptor gene expression levels in the presence of 
chemicals. Red bars: OR2T4. Green bars: OR10S1. Blue bars: OR2A7. The gene 
expression experiments were run 600 µM lilial and nonanal, and 1000 µM pinene. 
DMSO controls were compared to OR/chemical pairs for OR2T4, OR10S1, and 
OR2A7 and in all cases P > 0.05. 
Taken together, pinene is a confirmed ligand for OR2A7 and OR2T4, lilial is a 
confirmed ligand for OR2A7, OR2T4, and OR10S1, while undecanal is a confirmed ligand 
for OR2T4. Addition of these chemicals does not elicit an increase in the level of OR gene 
expression when compared to the DMSO control (Figure 2.8). Thus, the increase in GFP 
expression is due to signal transfer and not an increase in the number of olfactory receptors 
expressed. Farnesol does not result in a dose-response fit with OR2T4 or OR2A42; thus, it 
is not a ligand for these ORs. Although addition of farnesol to OR51B5 did result in a dose-
response fit, the response has an overall on/off behavior (except for the data point at 200 
μM farnesol). To test if farnesol generally increases the level of GFP expression in the 
presence of ORs, we measured the response of OR2W3 and OR2A7 upon addition of 
farnesol (Figure 2.9). In the presence of OR2W3 or OR2A7, farnesol elicits GFP 
expression, yet the data do not fit a dose-response curve. In conclusion, farnesol 
nonspecifically activates GFP expression in the OR-based sensors.  
 43 
 
Figure 2.9 – Dose-response curves of OR2A7 and OR2W3 with farnesol. 
2.4.7 Understanding the Chemical Activation Profile of OR2A7 and OR2T4. 
We determined the dose-response curves of OR2A7 and OR2T4 with chemicals that have 
stereochemistry and substructure different from those of the identified hits, pinene and 
lilial. Activation of the ORs is dependent on pinene stereochemistry. OR2A7 shows an 
18% weaker response with β-pinene than α-pinene, while the response of OR2T4 to β-
pinene is similar to the GFP expression of the no OR control (Figure 2.10A,B). Both 
OR2T4 and OR2A7 are activated by lilial. We probed the activation profile of OR2T4 and 
OR2A7 with 3-phenylbutyraldehyde (3PB), which retains the aldehyde found in lilial but 
lacks the tert-butyl group, and tert-butylbenzene (TBB), which lacks the aldehyde moiety 
but retains the phenyl and tert-butyl groups. We find that to activate OR2T4 and OR2A7, 
the tert-butyl group and the aldehyde side chain are necessary (Figure 2.10C,D). Although 
TBB shows an increase in the level of GFP expression at >600 μM, the no receptor control 




Figure 2.10 – Chemical activation profiles of OR2A7 and OR2T4. Dose-response 
curves of (A) OR2A7 with α-pinene and β-pinene, (B) OR2T4 with α-pinene and β-
pinene, (C) OR2A7 with lilial, 3-phenylbutyraldehyde (3PB), and tert-butylbenzene 
(TBB), and (D) OR2T4 with lilial, 3PB, and TBB. All measurements were carried out 
in triplicate and means ± the standard deviation are shown.  
Table 2.2 – Goodness of fit (R2) for dose-response curves. 
Figure  OR Chemical  R2 
Figure 2.5A, 
Figure 2.10A 
OR2A7 α-pinene 0.98946 
Figure 2.5A, 
Figure 2.10B 
OR2T4 α-pinene 0.99269 
Figure 2.5B, 
Figure 2.10C 
OR2A7 lilial 0.97004 
Figure 2.5B, 
Figure 2.10D 
OR2T4 lilial 0.99854 
Figure 2.5B OR10S1 lilial 0.99623 
Figure 2.5C OR51B5 farnesol  0.99585 
Figure 2.5D OR2T4 undecanal 0.90762 
Figure 2.5D OR10S1 nonanal 0.99651 
Figure 2.10A OR2A7 β-pinene  0.99659 
Figure 2.10C OR2A7 tert-butylbenzene  0.99853 
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2.5 Conclusion 
Here, we leveraged a previously engineered GPCR-based yeast sensing strain to 
generate sensors for seven ORs found in the human colon. Yeast’s robustness and rapid 
doubling time allowed us to quickly screen each of the seven colon ORs against 57 
chemicals and deorphanize two receptors, OR2T4 (α-pinene, lilial, and undecanal) and 
OR10S1 (lilial), and identify two new inexpensive ligands for OR2A7 (α-pinene and lilial). 
The rapid deorphanization workflow can be repeated to deorphanize other ORs and can be 
used, in the future, to identify the endogenous ligands of OR2T4, OR10S1, and OR2A7 in 
the colon. The yeast-based sensor used in this work links the human ORs to GFP expression 
via yeast Gα subunit GPA1. Sometimes, an OR is activated by different ligands depending 
on the Gα subunit to which they couple.24,25 Sometimes, ORs are activated by a ligand 
independent of the Gα subunit to which it couples, and using Golf enhances the signal.26,27 In 
the future, the OR/ligand pairs identified in this work can be coupled to Golf to determine 
the situation under which they fall. This can be accomplished using the mammalian OR 
sensor system that expresses Golf5,28 or by expressing Golf in yeast. 
We did not find ligands for OR2A42, OR2L13, OR2W3, or OR51B5. Although these 
ORs are expressed in yeast, it is possible that they are not coupling to the yeast machinery. 
Alternatively, ligands for these receptors may not be present among the 57 chemicals 
tested. Deorphanization of these ORs will likely require the use of Golf/GPA1 fusion protein 
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CHAPTER 3. IDENTIFICATION OF THREE 
ANTIMICROBIALS ACTIVATING SEROTONIN RECEPTOR 4 
IN COLON CELLS 
Reprinted with permission from: 
 
Yasi, E. A., Allen, A. A., Sugianto, W. and Peralta-Yahya, P. ACS Synth. Biol. 2019, 8 
(12) 2710-2717. Copyright 2019 American Chemical Society. 
3.1 Abstract 
The serotonin receptor 4b (5-HTR4b) is expressed throughout the gastrointestinal 
tract, and its agonists are used in the treatment of irritable bowel syndrome with 
constipation (IBS-C). Today, there are no rapid assays for the identification of 5- 
HTR4b agonists. Here, we developed a luciferase-based 5-HTR4b assay capable of assessing 
one compound per second with a 38-fold dynamic range and nM limit of detection for 
serotonin. We used the assay to screen more than 1000 natural products and anti-infection 
agents and identified five new 5-HTR4b ligands: hordenine, halofuginone, proflavine, 
ethacridine, and revaprazan. We demonstrate that hordenine (antibiofilm), halofuginone 
(antiparasitic), and revaprazan (gastric acid reducer) activate 5-HTR4b in human colon 
epithelial cells, leading to increased cell motility or wound healing. The 5-HTR4b assay can 
be used to screen larger pharmaceutical libraries to identify novel treatments for IBS-C. 
This work shows that antimicrobials interact not only with the gut microbiota, but also with 
the human host. 
3.2 Introduction 
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In humans, 95% of serotonin (5-HT) is found in the gastrointestinal (GI) tract,1 where 
release and reception of 5-HT transmits information from the gut lumen to gut nerve cells 
and smooth muscles. Of the seven 5-HT receptor families, 5-HTR4 is broadly expressed in 
the gut: on nitrergic neurons that control smooth muscle relaxation, cholinergic and 
nitrergic neurons that control muscle contraction and relaxation, enterocytes that control 
chemical transport, and enteroendocrine cells that control the secretion of gastrointestinal 
hormones.2,3 Specifically, 5-HTR4b is highly expressed in the jejunum, ileum, and colon.
4 
5-HTR4 has been implicated in irritable bowel syndrome (IBS), which affects 15% of the 
world population.4,5 Agonists of 5-HTR4 are used for the treatment of irritable bowel 
syndrome with constipation (IBS-C), relieving constipation, abdominal pain, and bloating. 
One of the major challenges in identifying novel 5-HTR4 agonists is the dearth of 5-
HTR high-throughput assays to rapidly assess large libraries of chemicals. The two-day 
culture time required to test cell motility using colon cells, which naturally express 5-HTR4, 
would be time-prohibitive for a primary screening tool. Commercial G-protein coupled 
receptor (GPCR)-based assays, such as SelectScreen (Thermo Fisher) and gpcrMAXSM 
(Eurofins) lack screens for any member of the 5-HTR4 family. To our knowledge, only one 
large-scale 5-HTR4 screen has been performed to date, against 976 ToxCast chemicals 
using guinea pig brain tissue and radio-labeled ligand displacement.6  
Previously, we engineered a fluorescence-based 5-HTR4b assay in yeast by linking 
expression of human 5-HTR4b on the yeast surface to green fluorescent protein (GFP) 
expression.7 The fluorescent reporter, however, posed some practical limitations. 
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Fluorescent readout requires a 4 h chemical incubation step for robust GFP expression, and 
a high-throughput flow cytometer for signal readout, thus limiting the assay throughput to 
one 96-well plate per hour. Additionally, the GFP-based 5-HTR4 assay has only a 3-fold 
dynamic range and one order of magnitude linear range after activation with serotonin.  
 
Figure 3.1 – Luciferase-based 5-HTR4 assay development. (A) Workflow for the 
identification and validation of HTR4b agonists. (B) Luciferase-based 5-HTR4 assay: 
human 5-HTR4b was expressed on the cell surface of a yeast engineered to link 
receptor activation to reporter to luciferase gene expression via the yeast mating 
pathway. (C) 5-HTR4-assay optimization at a pH = 7 and 100 mg/L serotonin.  
Here, we developed a luciferase-based 5-HTR4b assay with an overall assay time of 
2.5 h, enabling the use of a luminescent plate reader, and achieving a screening throughput 
of one compound per second. Next, we used the assay to screen 1206 compounds coming 
from two commercial chemical libraries, a natural products library and an anti-infection 
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library, and discovered five previously unidentified 5-HTR4b ligands. We validated three 
of the five ligands, hordenine, halofuginone, and revaprazan, as 5-HTR4b agonists in 
mammalian cells as they increase motility or wound healing in human colon epithelial 
cells. (Figure 3.1A). 
This work has three significant outcomes. First, the same compound discovery 
workflow can be used, in the future, to screen pharmaceutical libraries for the identification 
of novel 5-HTR4b agonists for the treatment of IBS-C. Second, the increased assay signal 
provided by the luciferase reporter, when compared to the GFP reporter, should enable the 
generation of other high-throughput GPCR-based assays by simply swapping the receptor 
from the cell surface. Third, as antibiofilm (hordenine) and antiparasitic (halofuginone) 
agents affect colon cell motility and/or wound healing, antimicrobials may interact not only 
with the gut microbiota, but also with the human host leading to potential changes in gut 
movement and secretion. Finally, with a 5-HTR4b high-throughput assay in hand, we can 
now screen gut microbiota metabolites to further understand the link between host and gut 
microbiome.  
3.3 Results 
3.3.1 Luciferase-Based 5-HTR4b Assay Development. 
We replaced the GFP reporter from our GFP-based 5-HTR4b assay
7 with NanoLuc 
luciferase,8 which we optimized for yeast expression (Figure 3.1B). As the pH of the GI 
tract hovers between 5.7 and 7.4, we optimized the assay at a pH of 7. The 5-HTR4b assay 
is composed of two steps, (i) ligand incubation leading to luciferase expression, and (ii) 
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luciferase substrate incubation leading to luminescence. By co-optimizing both incubation 
steps using serotonin, we concluded that a 2 h ligand incubation followed by a 30 min 
luciferase substrate incubation results in the fastest overall assay conditions (2.5 h) with 
the highest signal increase after activation (38-fold) (Figure 3.1C). Of note, multiple 96-
well plates can be incubated simultaneously, as reading the plate for luminescence takes 2 
min. 
3.3.2 Luciferase-Based 5-HTR4b Assay Validation. 
We demonstrate that the assay detects three known 5-HTR4 agonists for the 
treatment of IBS-C: tegaserod, prucalopride, and mosapride,9,10 and four other agonists 
used to treat gastroesophageal reflux (cisapride),11 depression (RS67333),12 anxiety 
(zacopride),13 and nausea (metoclopramide)10,14 (Figure 3.2A−H). To verify that the 
agonists led to cell luminescence due to 5-HTR4b activation and not via an alternative 
mechanism, we performed dose-response curves with the agonists using a control strain 
carrying the luciferase reporter plasmid and a blank plasmid in lieu of 5-HTR4b. On the 
basis of EC50s, the potency of the agonists toward 5-HTR4b are tegaserod (0.3 nM) > 
RS67333 (11.0 nM) > prucalopride (41.0 nM) > cisapride (69.9 nM) > serotonin (155.0 
nM) > mosapride (256.4nM) > zacopride (616.0 nM) > metoclopramide (7.4 μM). These 
results agree with previous studies that identified tegaserod and RS67333 to be more potent 
than serotonin,15,16 and zacopride and metoclopramide to be less potent.17−19 Taken 
together, the luciferase-based HTR4b assay is capable of identifying drugs with EC50s 
ranging from the low nM to the μM level.  
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Figure 3.2 – Validation of the 5-HTR4 assay. 5-HTR4 assay dose-response curves with 
known 5-HTR4 agonists: (A) cisapride, (B) metoclopramide, (C) mosapride, (D) 
prucalopride, (E) RS-67333, (F) serotonin, (G) tegaserod, (H) zacopride. Data was 
collected in triplicate. Shown are means ± s.d.  
3.3.3 5-HTR4b Assay High-Throughput Screening Validation. 
We validated the assay for 96-well plate high-throughput screening using a 3-day 
plate uniformity experiment20 (Figure 3.3). The assay had an average Z factor of 0.74 and 
an average coefficient of variation of 7.7%, meeting the two statistical parameters for high-
throughput assay acceptance, i.e., a Z factor of >0.521 and a CV < 10%.22 
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Figure 3.3 – Three-day 96 well-plate validation assay. Luminescence data with no, 
medium and high levels of serotonin. No obvious intra-plate edge effects or drift 
observed. The signal activation levels did fluctuate from day to day, but all raw 
midpoint CVs were below 20%. 
3.3.4 Identifying Novel 5-HTR4b Ligands. 
GPCRs expressed in the GI tract tend to bind gut microbial metabolites. For 
example, GPR41, GPR43, and GPR109 bind microbiota produced short chain fatty 
acids.23−25 We hypothesize that 5-HTR4b may bind microbial natural products. To explore 
the range of biological compounds that 5-HTR4b may bind, we used the assay to screen a 
commercial 803-member chemical natural products library. First, to understand the 
chemical diversity of the library, we broke down each library member into 23 chemical 
descriptors to perform a principal component analysis (Figure 3.4A, Table 3.1). The 
principal components (PC axes) reflect the common and unique variances of the chemical 
descriptors with the top three PCs accounting for 64% of the cumulative variances, with 
PC1, PC2, and PC3 capturing 45%, 11%, and 8% of the total variance, respectively. On 
the basis of their PC scores, chemicals can be separated into eight chemical spaces (CS) 
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(Table 3.2). All chemical spaces are populated by compounds in the natural products 
library, 
 
Figure 3.4 – 5-HTR4 assay identifies natural products as novel ligands. (A) Principal 
component analysis of natural products library with 5-HTR4b screening hits 
highlighted. (B) 803-member natural product library screening results. The 
compounds were screened using the 5-HTR4b assay in singlets. Z-scores were 
normalized to the serotonin positive control, which was set to 1 (dotted line). (C) 
Dose-response curves of the four validated natural product hits. Data was collected 
in triplicate. Shown are means ± s.d.  
Table 3.1 – Table of chemical descriptors used in PCA analysis 
Descriptors Abbreviations Descriptors Abbreviations 
Molecular Weight MW Ring system count RSC 
Carbon atom count CAC Size of largest ring SLR 
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Hydrogen atom count HAC Van der Waals surface area VSA 
Oxygen atom count OAC Amine - 
Nitrogen atom count NAC Alcohol - 
Hydrogen-bond donors HBD Ether - 
Hydrogen-bond acceptor HBA Aldehyde - 
Rotatable bonds RB Ketone - 
Stereocenter count SC Carboxylic Acid - 
Topological polar surface 
area TPSA Ester - 
Number of rings NOR Amide - 
Aromatic ring count ARC   
Table 3.2 – Chemical space composition of the natural product library. 
Chemical 
Space PC1 PC2 PC3 Members 
Population 
(%) Chemical characteristics 
1 - - - 128 16 Mix of aromatics and groups 
containing N and O atoms  
2 + - - 88 11 Steric, heterocyclic with O-
containing functional groups 
3 - - + 177 22 small heteroaromatics (fused 
rings) with O-containing 
functional groups 
4 + - + 90 11 Adjacent to CS 3, hence similar 
trend, except higher C-atom count 
5 + + - 47 6 chiral with multiple functional 
groups (phosphate, sulfate, N and 
O-containing functional groups) 
6 - + - 124 16 Two distinct groups: A) long C-
tail containing only N or O-
functional group. B) complex 
heterocyclic (individual benzene 
rings) having both N and O-
containing functional groups 
7 + + + 49 6 hydrocarbons and cyclic rings 
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8 - + + 98 12 Adjacent to CS 6, hence similar 
trend, except heteroaromatics are 
fused rings    
Total: 801 100  
indicating its chemical diversity. CS3, composed of small heteroaromatics with O-
containing functionality, is the highest populated CS, containing 22% of all chemicals in 
the library. The least populated CSs are CS5 and CS7, each containing 6% of all the 
chemicals tested. In the future, the chemical diversity of the library could be improved by 
introducing more compounds with chiral centers and cyclic rings.  
The screening of the natural products library resulted in 12 hits: serotonin, 
tryptamine, 3-indolebutyric acid, L-5-hydroxy-tryptophan (L-5-HTP), D/L-5-
hydroxytryptophan (5-HTP), hordenine, genistin, neomangiferin, baohuoside I, baicalein, 
halofuginone, and nalidixic acid (Figure 3.4B). Previously, tryptamine26 and 5-HTP27 have 
been shown to bind 5-HTR4, and baicalein
28 has been shown to bind 5-HTR7. Hordenine, 
nalidixic acid, halofuginone, 3-indolebutyric acid, genistin neomangiferin, and baohuoside 
I have not been previously shown to bind 5-HTR4.
29  
To confirm the natural products library hits, we ran dose-response curves using the 
5-HTR4b assay strain, and a control strain carrying the luciferase reporter and a blank 
plasmid in lieu of 5-HTR4b. We confirmed tryptamine and 5-HTP to be ligands of 5-HTR4. 
We could not confirm 3-indolebutyric acid, nalidixic acid, baicalein, genistin, baohuoside 
I, and neomangiferin as ligands of 5-HTR4b (Figure 3.5). We find, for the first time, that 
hordenine (EC50 102.4 μM) and halofuginone (EC50 1.2 μM) are HTR4b ligands (Figure 
 61 
3.4C). Except for L-5-HTP, all natural products hits, i.e., hordenine, tryptamine, serotonin, 
and halofuginone, belong to CS8.  
 
Figure 3.5 – Dose-response curves of the six natural product hits that could not be 
validated 
3.3.5 High-Throughput Screening of a 403-Member Anti-infection Library. 
Hordenine has antibiofilm activity against Pseudomonas aeruginosa,30 and 
halofuginone is used for the treatment and prophylaxis of cryptosporidiosis in ruminants.31 
Intrigued by the fact that antimicrobial agents activate 5-HTR4b, we explored whether other 
antimicrobials activate 5-HTR4b. To do this, we screened a commercial 403-member anti-
infection library at two chemical concentrations: (i) 10 μM, the same concentration used to 
screen the natural products library, and (ii) 1 μM due to potential toxicity effects of the 
anti-infection compounds on yeast. On the basis of Z-scores, the 10 μM screen resulted in 
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four hits: proflavine, ethidium bromide, ethacridine, and hordenine, while the 1 μM screen 
also resulted in four hits: isepamicin, osalmid, revaprazan, and borneol (Figure 3.6A). We 
attribute the absence of 1 μM hits in the 10 μM screen to toxicity issues, given that the 5-
HTR4b assay is in cells. Neither proflavine, ethacridine, nor revaprazan have been 
previously shown to activate any serotonin receptor.29  
 
Figure 3.6 – Screening of a 403 member anti-infective library. (A) Anti-infective 
compound screening results at 10 μM (top) and 1 μM (bottom). The compounds were 
screened using the 5-HTR4b assay in singlets. Z-scores were normalized to the 
serotonin positive control, which was set to 1 (dotted line). (B) Dose-response curves 
of the 3 validated anti-infective hits. (C) Toxicity results after yeast was incubated 
for 2.5 h with varying concentration of the anti-infective hits. Data was collected in 
triplicate. Shown are means ± s.d. 
To confirm the anti-infection library hits, we ran dose-response curves using the 5-
HTR4b assay strain, and a control strain carrying the luciferase reporter and a blank plasmid 
in lieu of 5-HTR4b. We confirmed proflavine (EC50 6 μM), ethacridine (EC50 2.9 μM), and 
revaprazan (EC50 270 nM) as HTR4b ligands (Figure 3.6B). We noticed a sharp decline in 
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receptor activation at high compound concentrations. A toxicity assessment of these 
compounds shows they are toxic at high concentrations (Figure 3.6C). We could not 
confirm ethidium bromide, isepamicin, osalmid, or borneol as 5-HTR4b ligands (Figure 
3.7).  
 
Figure 3.7 – Dose-response curves of the four anti-infection hits that could not be 
validated 
3.3.6 Validating 5-HTR4b Ligands via Wound Healing and Motility Assays in 
Colon Epithelial Cells. 
To assess the biological relevance of the five 5-HTR4b identified ligands, we tested 
their ability to activate 5-HTR4b in mammalian cells by inducing cell motility and wound 
healing in human colon epithelial cells (Caco-2). Caco-2 cells endogenously express 5- 
HTR4
32 and activation of 5-HTR4 using the agonist tegaserod leads to increased cell 
motility, wound healing, and cell proliferation.32 Tegaserod (Zelmac) is used for the 
treatment of IBS-C. To test cell motility, we used culture inserts to create a cell free zone 
to avoid cell death and damage.33 Revaprazan and hordenine significantly (P < 0.01) 
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increase cell motility (Figure 3.8A,B). Wound healing was tested by creating a scratch in 
the cell monolayer using a pipet tip. This more closely mimics in vivo wound healing by  
 
Figure 3.8 – Antimicrobials enhanced colon epithelial cell motility and wound 
healing. (A) Representative photomicrographs of the colon cell (Caco-2) migration 
assay after 48 h with phosphate buffer control (PBS), tegaserod (5-HTR4B agonist, 1 
μM), serotonin (1 μM), and the five 5-HTR4B ligands (10 μM). For all 
photomicrographs for migration after 24 and 48 h, see Figure 3.9. (B) Quantification 
of the colon cell migration assay after 48 h. The cell migration elicited by revaprazan 
and hordenine is similar to that observed by serotonin and tegaserod, and it is 
statistically significantly different than the PBS control (P < 0.01). (C) Representative 
photomicrographs of the Caco-2 wound healing scratch assay after 48 h with control 
(PBS), tegaserod (1 μM), serotonin (10 μM), and the 5 identified 5-HTR4B ligands (10 
μM). For all photomicrographs of the wound healing scratch assay after 24 and 48 h, 
see Figure 3.10. (D) Quantification of the colon cell wound healing scratch assay. The 
wound healing elicited by revaprazan, halofuginone, and hordenine is statistically 
significantly different than the PBS control (P < 0.05).  
creating cell damage, such as increasing reactive oxygen species at the wound boundary.34 
Incubation of Caco-2 cells with hordenine, halofuginone, and revaprazan resulted in a 
statistically significant increase in wound healing (P < 0.05) when compared to the buffer 
control (Figure 3.8C,D). Proflavine and ethacridine did not result in a significant increase 
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in either colon cell motility or wound healing. Taken together, revaprazan and hordenine 
results in both increased cell motility and wound healing, while halofuginone results only 
in increased wound healing.  
Figure 3.9 – Photomicrographs of colon cell migration assay after 0, 24, and 48 hours 
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Figure 3.10 – Photomicrographs of colon cell scratch would healing assay after 0, 24, 
and 48 hours. 
3.3.7 Relevance of the Newly Identified 5-HTR4b Agonists in the Gut. 
Hordenine is present in malted barley and beer (strong beer: 5.16 mg/L; Pilsner: 2.7 
mg/L35,36). Assuming all hordenine consumed reaches the colon, a pint of Pilsner beer 
would need to be ingested to reach concentrations that were observed to increase colon cell 
motility and wound healing. Other sources of hordenine are athletic performance and 
weight loss supplements.37  
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Halofuginone is used for the treatment and prophylaxis of cryptosporidiosis in 
ruminants31 with a maximum residue limit of 10−30 μg in bovine muscle, fat, kidney, and 
liver.38 Chickens treated with halofuginone can expect to lay eggs with up to 60 μg/kg 
halofuginone.39 One may only need to eat half a jumbo egg to reach the levels seen to 
increase colon cell wound healing, assuming all halofuginone reaches the colon.  
Revaprazan is a proton pump inhibitor that reduces gastric acid secretion and 
reduces inflammation caused by Helicobacter pylori.40 At a daily dose of 200 mg/day and 
assuming it all reaches the colon, the concentration of revaprazan in the gut would be 983.6 
μM, which is more than 3000 times higher than the EC50 of 270 nM. 
3.4 Discussion 
We have developed a rapid and robust luciferase-based 5-HTR4b assay in yeast with 
a 38-fold dynamic range and a limit of detection in the nM level for serotonin. We applied 
this assay to screen more than 1000 chemicals and identified five new 5-HTR4b ligands. 
Three of these ligands, hordenine, halofuginone, and revaprazan, activate 5-HTR4b in 
mammalian cells, eliciting colon cell motility and/or wound healing. The 5-HTR4b assay 
can now be used to screen large pharmaceutical libraries to identify 5-HTR4b agonists for 
the treatment of IBS-C. The increased sensitivity of the 5-HTR4b luciferase assay over our 
previous GFP-based assay should enable the generation of assays for other 5-HTRs, 
including 5-HTR1, the pharmaceutical target of antidepressant drugs.
41  
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A current limitation of the luciferase-based 5-HTR4b assay is the relative high 
background in the no receptor control. In the absence of receptor, there is free floating Gαβλ, 
which does not need to be dissociated to activate the kinase cascade leading to increased 
gene expression.42 Sequestering Gαβλ by expression of the yeast endogenous GPCR (Ste2) 
may reduce basal luciferase levels in the control strain. Additionally, mixtures of 
heterologous GPCR/Ste2 in the sensor strains could achieve lower basal expression, but 
the system would have to be tuned.  
The identification of antimicrobials binding 5-HTR4 is of profound impact to 
understanding conditions mediated by serotonin receptors. As shown in this work, 
antimicrobials may not only interact with the gut microbiota, but also with the human host 
leading to potential changes in gut movement and secretion. Changes in bowel movements 
and gastrointestinal hormone secretion may at least be partially caused by activation of 
serotonin receptors. Thus, our findings have implications for the treatment of IBS-C, which 
can be treated using antibiotics,43 and more generally to conditions related to serotonin 
receptor activation, such as depression. Finally, although antimicrobials have not been 
extensively considered as activating GPCRs, the availability of this high-throughput GPCR 
assay will enable the analysis of other GPCRs for their binding of antimicrobials. 
3.5 Methods 
3.5.1 Materials 
Serotonin hydrochloride (S0370) was purchased from TCI Chemicals. RS67333 
hydrochloride (SML1882), tegaserod malate (SML1504), metoclopramide 
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monohydrochloride (M0763), prucalopride (SML1371), cisapride (CDS021610), 
mosapride citrate (M2946) and zacopride hydrochloride hydrate (SML0081) were 
purchased from Sigma-Aldrich. Nano-Glo® Luciferase Assay System (N1120) was 
purchased from Promega. The natural products library (L1400) and the anti-infection 
library (L3100) were purchased from Selleck Chemicals. Breathe Easy Sealing Membrane 
was purchased from Electron microscope services. Luminescence white 96-well plates 
were purchased from Thermo 
3.5.2 Luciferase-Based 5-HTR4b Assay Construction. 
NanoLuc was codon-optimized for Saccharomyces cerevisiae, commercially 
synthesized and cloned into pKM58644 between NcoI and NheI to generate pRS415-Leu2-
pFIG1-NanoLuc (pEY15). pEY15 was sequenced verified using primer EY248. To 
construct the 5-HTR4b assay, pEY15, and pESC-His3-pTEF1-HTR4 (pTMC18
7) were co-
transformed into the PPY14044 (W303 Δfar1 Δste2, Δsst2) to generate PPY1808. To 
construct the controls strain lacking 5-HTR4b, PPY140 was co-transformed with pEY15 
and an empty vector (PPY111) to generate PPY1809. 
3.5.3 Luciferase-Based 5-HTR4b Assay. 
3.5.3.1  Serotonin Detection. 
An overnight culture of PPY1808 was used to inoculate 20 mL of synthetic 
complete medium with 2% glucose lacking histidine and leucine (SD(HL−) to an OD600 = 
0.06. After 18 h at 15 °C (150 rpm), PPY1808 was centrifuged (3500 rpm, 10 min), and 
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resuspended to an OD600 = 1. In a white flat bottom 96-well plate, 190 μL of pH = 7 
SD(HL−), 8 μL of PPY1808, and 2 μL of serotonin (final concentrations 0−4.3 mM) were 
added. After the chemical incubation step (2 h, plates covered with Breathe Easy Sealing 
Membrane, 30 °C, 250 rpm), 20 μL of 1:100 mixture of NanoLuc substrate to NanoLuc 
buffer was added45 for the luciferase substrate incubation step well (30 min, plates covered 
with Breathe Easy Sealing Membrane, 30 °C, 250 rpm). Luminescence was read 
immediately after luciferase substrate incubation in a Biotek Synergy 2 plate reader using 
default settings. For the time course assay, the cells were incubated at medium shaking 
speed in a Biotek Synergy 2.  
3.5.3.2 Screening of Known 5-HTR4 Agonists. 
The same protocol for serotonin detection was followed. Instead of 2 μL of 
serotonin the same volume of RS67333, zacopride, and metoclopramide in water or 
cisapride, mosapride, tegaserod, and prucalopride in DMSO were used to reach a final 
concentrations between 0 and 10000 nM. Dose-response curves were fitted using the dose-
response equation in Origin Pro 2016. EC50s were derived from this function by Origin.  
3.5.4 High-Throughput Chemical Compound Screening. 
3.5.4.1 High-Throughput Assay Validation. 
A three-day assay validation was performed according to Iversen, et al.
 20 The same 
serotonin detection protocol was followed. High signal wells have 5 μM of serotonin, mid 
signal wells have 60 nM of serotonin, and low signal wells have 0 nM of serotonin. Data 
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were analyzed in the Excel template provided by Iversen, et al.20 using activation assay 
settings with statistics calculated for single replicate screens.  
3.5.4.2 Chemical Compound Screening. 
The same protocol used for serotonin detection was followed. Instead of 2 μL of 
serotonin, and 2 μL of chemical in DMSO or water from the natural product library (Selleck 
Chemicals L1400, 803 chemicals) or the anti-infection compound library (Selleck 
Chemicals L3100, 403 chemicals) was used to a final concentration of 10 μM (and 1 μM 
in the case of the anti-infection library). Each plate contained three negative control wells 
with DMSO or water and three positive controls with serotonin (5 μM) in DMSO. Natural 
product hits were identified using a Z-score as calculated below. The Z-scores were 
normalized to the serotonin positive control in each 96-well plates.  
𝑧 − 𝑠𝑐𝑜𝑟𝑒 =
𝑛𝑎𝑡𝑢𝑟𝑎𝑙	𝑝𝑟𝑜𝑑𝑢𝑐𝑡 − 𝑚𝑒𝑎𝑛	𝐷𝑀𝑆𝑂
𝑆𝑇𝐷𝑒𝑣	𝐷𝑀𝑆𝑂  
3.5.5 Principal Component Analysis. 
3.5.5.1 Data Gathering. 
Simplified molecular-input line-entry system (SMILES) for 801 of the 803 
chemicals in the natural product library (lanolin and tea polyphenols are mixtures) were 
retrieved from Selleck Chemicals and PubChem to obtain data on 23 chemical descriptors 
with 8 descriptors representing chemical functional groups, and 15 descriptors according 
to Wenderski, et al.46 The SMILES were inputted into Instant JChem (ChemAxon). 
3.5.5.2 Data Analysis. 
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PCA was run using Solo software (Eigenvector Research). Evaluation of the three 
PCs was conducted using Solo based on Eigenvalues. The three PC scores data from Solo 
were used to create 3-D scatterplots in MATLAB. The scatterplots were divided into eight 
distinct chemical spaces based on their 3-D coordinates.  
3.5.6 Toxicity assessment 
An overnight culture of PPY1808 in SD(HL- ) was used adjusted to an OD of 1. In 
a 96 well plate, 190 µL of pH=7 SD(HL- ) , 8 µL of PPY1808, and 2 µL of DMSO, 
ethracridine in DMSO, proflavine in water, or rezaprazan in DMSO (final concentrations 
0, 10µM, 100 µM) were added. The plate was incubated in a Tecan Infinite M200 Pro plate 
reader at 30 °C with shaking and OD600 was measured at 2.5 hours 
3.5.7 Colon Cell Wound Healing Assay. 
Caco-2 cells (ATCC HTB-37) were grown at 37 °C with 5% CO2 in Dulbecco’s 
Modified Eagle Medium (DMEM) with high glucose, sodium pyruvate and GlutaMAX or 
L-glutamine (Gibco) supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin. Media was changed every 2−3 days. Once 70−80% confluence was reached 
in T25 flasks, cells were detached using 0.05% trypsin−EDTA and diluted to a final volume 
of 15 mL with growth media. Cells were seeded into a 48 well plate and allowed to grow 
until they reached 90−100% confluence. Wounds were made with a P200 pipet tip and 
cells were washed with PBS. Cells were incubated in fresh growth media with either PBS, 
10 μM of chemical hit or 1 μM of serotonin or tegaserod. Images were taken on a Leica 
inverted microscope at 0, 24, and 48 h. ImageJ MRI Wound Healing Tool [http://dev. 
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mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool] was used to measure 
wound size.  
3.5.8 Cell Migration Assay. 
Caco-2 cells were maintained as stated above. Ibidi culture inserts were placed in a 
24 well plate, and 70 μL of cells ((1−2) × 105 cells/mL) were placed in both insert wells. 
Cells were grown overnight to allow for attachment. Inserts were removed with sterile 
tweezers. Cells were washed twice with PBS then incubated with either PBS, 10 μM of 
chemical hit or serotonin, or 1 μM of tegaserod. Images were taken on a Leica inverted 
microscope at 0, 24, and 48 h. ImageJ MRI Wound Healing Tool was used to measure the 
cell free zone.  
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CHAPTER 4. FUTURE OUTLOOK 
4.1 Conclusions and Future Outlook  
4.1.1 Expanding our knowledge of ectopic olfactory receptors in the colon  
In Chapter 2, a rapid yeast-based OR sensor platform deorphanized OR10S1 and 
OR2T4 and found an alternative ligand for OR2A7. These ectopic ORs expressed in the 
colon do not have known functions in the colon yet. With known OR-ligand pairs now 
available, in vitro and in vivo experiments can be performed to probe downstream signaling 
effects to determine possible roles in the colon. This can improve our understanding of 
disease states and can lead to ORs as drug targets. The yeast-based sensors can be used to 
screen therapeutics for these conditions. Additionally, the colon is rife with microbial 
metabolites. OR51E1 and OR51E2 are well-studied colon ORs and are known to interact 
with our gut microbiota 1,2. OR2A7, OR2T4, and OR10S1, most likely interact with our 
gut microbiota as well. The yeast-based OR sensors can be used to screen microbial 
metabolites to find if any interactions exist, giving us insight into their endogenous role in 
the colon.   
4.1.2 Future screening applications of the serotonin receptor 4 yeast-based 
assay 
In Chapter 3, a serotonin receptor yeast-based assay was improved for HTS 
applications by simply switching the reporter from GFP to luciferase. This significantly 
improved the dynamic range and throughput of the sensor and allowed to test large 
chemical compound libraries for drug discovery applications. 5-HTR4 is highly expressed 
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throughout the colon and is the pharmaceutical target for irritable bowel syndrome with 
constipation (IBS-C). To date, no microbial metabolites have been found to interact with 
the receptor. The yeast-based assay can be used to explore the microbiome connection to 
gastrointestinal disorder by screening metabolites and possibly linking certain microbes to 
disease states. 5-HTR4 agonists are used to treat IBS-C, however, only two drugs are FDA 
approved. This is because they can have adverse side effects, such as heart attack, 
depression, and suicidal ideations. The yeast-based assay can be used to screen large 
diverse libraries to identify new chemotypes with the potential for less off-target effects. 
4.1.3 Improving heterologous GPCR coupling in yeast 
In Chapters 2 and 3 the endogenous yeast Gα, GPA1, was used to couple human 
GPCRs to the yeast mating pathway. As in humans, ORs couple to adenylate cyclase via 
Gαolf, non-functional coupling of the OR to the yeast Gα could be a reason why we could 
not deorphanize some ORs and most of them had a ~2-3-fold increase in signal after 
activation. Another reason could be that the library tested was simply too small (57 
chemicals) compared to the chemical library sizes used for ORs and more generally GPCR 
deorphanization that is in the hundreds3 to hundreds of thousands4. Previously, 
GPA1/human Gα chimeras have been used to couple human GPCRs to the yeast mating 
pathway. This method has variable success5, 6. In this method, the last five amino acids on 
the α5 helix of the Gα are introduced at the end of GPA1. The α5 helix interacts with 
transmembrane 5 and 6 (TM 5 and TM 6) of activated GPCRs7, 8.  From structural studies, 
we know that 21 amino acids in Gαs under 4 Å away from β2AR form approximately 35 
interactions7.  The last five amino acids only account for nine interactions (between 3.0 -
3.8 Å) and could show the lack of robust success in practice. In addition to interactions 
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between TM 5 and TM 6 of a GPCR and Gα, the intracellular loop 2 also interacts with 
residues in β1 and β3 strands of the Gα7. Engineering the yeast Gα by swapping the whole 
α5 helix and changing the β1 and β3 strand residues to match human Gαs is a promising 
method to increase coupling of GPCRs whose Gα is known. 
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APPENDIX A. SCREENING FOR SEROTONIN RECEPTOR 4 
AGONISTS USING GPCR-BASED SENSOR IN YEAST 
Yasi, E. A., and Peralta-Yahya, P. Methods Mol. Biol. Accepted.  
 A1.1 Summary 
More than 30% of all pharmaceuticals target G-protein coupled receptors (GPCRs). 
Here we present a GRPC-based screen in yeast to identify ligands for human serotonin 
receptor 4 (5-HTR4). Serotonin receptor 4 agonists are used for the treatment of irritable 
bowel syndrome with constipation. Specifically, the HTR4-based screen couples activation 
of 5-HTR4 on the yeast cell surface to luciferase reporter expression. The HTR4-based 
screen has a throughput of one compound per second allowing the screening of more than 
a thousand compounds per day. 
A1.2 Introduction 
There are over 800 G-protein coupled receptors (GPCRs) expressed in humans.1 
These receptors have a plethora of functions from sensing odorants2 and flavors3 to binding 
neurotransmitters4 to controlling blood pressure and heart rate5. Currently, approximately 
34% of FDA approved drugs target GPCRs.6 Notably, levodopa targets dopamine receptors 
in the brain to treat Parkinson’s disease,7 sumatriptan targets serotonin receptors 1B and 
1D to treat migraines,8 and propranolol targets beta adrenergic receptors to treat 
hypertension.9 Some over-the-counter supplements also target GPCRs, such as melatonin, 
a sleep aid.10  With the vast consequences that GPCRs have on human health and 
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physiology, high-throughput assays are needed to rapidly identify ligands, synthetic and 
endogenous, to further understand their downstream effects.  
Mammalian-based GPCR assays have long been used to detect GPCR activation. 
Indeed, several commercial kits are available to read out endogenous GPCR activation, 
including cAMP accumulation, which can be linked to cell fluorescence (e.g. 
CatchPointTM cAMP, Molecular Devices), calcium flux (e.g. FLIPR® Calcium Assay 
Kits, Molecular Devices), or luminescence.11-14 A general challenge of using mammalian 
cell-based assays for the identification of GPCR ligands is that mammalian cells 
endogenously express tens of GPCRs (e.g. 75 different GPCRs in HEK293).15 Thus, an 
assay phenotype can be trigged by a ligand that activates a different GPCR that transduces 
via the same Gα. Additionally, mammalian-based assays can be easily contaminated and 
are inherently slow due to their long doubling time and need for passaging. 
The yeast Saccharomyces cerevisiae is an ideal host for the development of GPCR-
based assays. Haploid yeasts have only two GPCRs: Ste2 (Matα) or Ste3 (Mata) respond 
to pheromones resulting in yeast mating, and Gpr1 responds to glucose.16 Detection of 
GPCR activation can be achieved by expressing a heterologous GPCR on the yeast cell 
surface, coupling it to the yeast mating pathway and expressing a reporter gene (e.g. green 
fluorescent protein, luciferase) under control of a mating pathway responsive promoter. To 
increase the heterologous GPCR signal three deletions are needed. Deletion of ste2/317 
increases signal transduction, and deletions of far1 and sst2 prevent cell cycle arrest and 
desensitization of the Gα subunit, respectively.18 The receptor Gpr1 couples to a distinct 
adenylate cyclase cascade that will prevent cross talk with the mating pathway.19 
Traditionally, the reporter gene has been an auxotrophic marker that enables growth 
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selection,20,21 which takes up to three days to see results of the assay. More recently, 
reporters that allow assay read outs in the same day, including green fluorescent protein  (4 
hours),22,23 and luciferase (1-2.5 hours),24,25 have been developed. 
Recently, we presented a GPCR-based assay that links serotonin receptor 4b (5-
HTR4b) to luciferase (NanoLuc)26 expression24. 5-HTR4b is expressed in the brain but is 
more prominently expressed throughout the gastrointestinal tract,27 where over 95% of 
serotonin is found.28 5-HTR4 is a drug target for irritable bowel syndrome with constipation 
and currently only a few FDA approved treatments target 5-HTR4, such as prucalopride 
(Motegrity™)29 and metoclopramide (Reglan®)30. The luciferase-based 5-HTR4 assay is 
fast, going from chemical incubation to signal read out in 2.5 hours. The ability to use a 
luminescence plate reader to detect reporter gene expression enables a screening rate of 1 
well per second.24 This method enables the high-throughput screening of vast chemical 
libraries for 5-HTR4b activation. 
A1.3 Materials 
i. Plasmids and Strains 
1. GPCR plasmid: PPY1192: pESC-His3-PTEF1-HTR4b-TCyc1 
2. No GPCR plasmid: PPY111: pESC-His3-PTEF1-TCyc1 
3. GPCR microscopy plasmid: PPY1133: pESC-His3-PTEF1-HTR4b-GFP-TCyc1 
4. Reporter Plasmid: PPY1740: pRS415-Leu2-PFIG1-NanoLuc 
5. Yeast sensor strain: PPY140: S. cerevisiae W303-1a MATa ade2-1, ura3-1, his3-
11, trp1-1, leu2-3, leu2-112, can1-100, Dfar1, Dsst2, Dste2 
6. 5-HTR4b-sensing strain: PPY140 carrying plasmids PPY1192 + PPY1740 
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7. Control sensing strain: PPY140 carrying plasmids PPY111 + PPY1740 
8. 5-HTR4b-GFP fusion strain: PPY140 carrying plasmid PPY1133 
ii. Yeast Media and Transformation Supplies 
1. Synthetic Dropout media lacking histidine and leucine with 2% glucose (SD (HL-))31 
2. Synthetic Dropout media lacking histidine and leucine with 2% glucose31 and 
buffered with potassium phosphate to pH 7 (SD(HL-) pH 7) 
3. Synthetic Dropout media lacking histidine with 2% glucose31 (SD(H-)) 
4. Yeast Peptone Dextrose media (YPD)32 
5. Tris-EDTA buffer (10x, pH 7.5): 100 mM Tris, 10 mM EDTA 
6. 1 M lithium acetate 
7. PEG 4000 50% (w/v) 
8. Solution 1: 8 mL diH2O, 1 mL 10x TE buffer, 1 mL 1M lithium acetate 
9. Solution 2:  800 µL 50% (w/v) PEG 4000, 100 µL 10x TE buffer, 100 µL 1M 
lithium acetate 
10. 10% KOH in water 
11. Salmon Sperm DNA: 1mg/mL in water, filter sterilized 
12. 1.5 mL Microcentrifuge tubes 
13. Petri dishes (100 x 15 mm) 
14. Test tubes (25 x 150 mm) 
15. Inoculation loops 
16. Flat toothpicks 
17. Parafilm 
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iii. Fluorescent Microscopy 
1. Poly-L-lysine slides with coverslip  
2. Calcofluor White Stain  
3. Confocal microscope 
iv. Luminescent Plate Reader Assay 
1. White opaque flat bottom 96 well plate  
2. Chemical library  
3. Chemical carrier solvent: e.g. Dimethyl Sulfoxide (DMSO). 
4. Breathe-Easy® membrane (Electron Microscopy Sciences) 
5. Promega Nano-Glo® Assay System (N1120) 
6. Luminescent enabled plate reader 
v. Software 
1. Microsoft Excel or similar program 
A1.4 Methods 
i. Preparation of 5-HTR4B-sensing, Control sensing, and 5-HTR4B-
GFP fusion strains 
1. Streak out PPY140 on a YPD agar plate and incubate at 30°C for 3 days. 
2. Patch a single colony on a fresh YPD agar plate using a sterile flat toothpick or a 
sterile loop and incubate at 30°C for 3 days. 
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3. Inoculate a small loopful of PPY140 into 5 mL YPD in a test tube. Grow overnight 
at 30 °C at 250 rpm.  
4. Add 1 mL of PPY140 overnight culture to 49 mL of fresh YPD and grow at 30 °C, 
250 rpm to an OD600 = ~0.6-0.8 which takes approximately 3-4 h.  
5. Centrifuge culture 3 min x 1800 g, decant, and resuspend cells in 50 mL diH2O.  
6. Centrifuge again 3 min x 1800 g, decant, and resuspend cells in 5 mL Solution 1.  
7. Centrifuge again 3 min x 1800 g, decant, and resuspend in 300 µL Solution 1.  
8. To generate the HTR4b sensing strain and empty vector control, combine in a 
microcentrifuge tube: 
• 300 µL of Solution 2  
• 50 µL of cells in Solution 1 (Step 7) 
• 5 µL of salmon sperm DNA (denatured at 95 °C for 5 mins, chilled on ice 
afterwards)  
• 500 ng of the GPCR plasmid (replace with No GPCR plasmid for control)  
• 500 ng of the Reporter Plasmids 
9. Incubate at 30°C, 250 rpm for 30 minutes. Heat shock the yeast by placing the tubes 
in a 42°C for 15 min. Spin cells down 1 min x 4,000 RPM.  
10. Resuspend the cell pellet in 150 µL of diH2O and plate on an SD(HL-) agar plate. 
Incubate plate at 30°C for 3 days [see Notes 1, 2].  
11. To generate the HTR4b-GFP fusion strain to test GPCR expression in yeast using 
fluorescent microscopy: use the same protocol as in Step 8 except replace GPCR 
plasmid with GPCR microscopy plasmid and do not use Reporter Plasmid. Plate on 
a SD(H-) agar plate. Incubate plate at 30°C for 3 days [see Notes 1, 2]. 
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12. Patch cells from a single colony on a fresh SD(H-) agar plate using a sterile flat 
toothpick or a sterile loop. Incubate plates at 30°C for 3 days.  
13. Patches can be stored at 4°C for up to one month wrapped in parafilm. 
ii. Fluorescent Microscopy 
1. Start an overnight culture of the HTR4b-GFP fusion strain by taking a small loopful 
of the patch and inoculating 5 mL of SD(H-). Shake at 30°C and 250 rpm. [see Note 
3].    
2. The next day, use the overnight media to inoculate 20 mL of SD(H-) to an OD600 of 
0.06. Incubate the culture at 15 °C, 150 rpm for 18h. 
3. Centrifuge culture 10 min x 3500 rpm, decant, and resuspend cells in 200 µL SD(H-). 
4. To a microscope slide, layer: 
• 2 µL of the cells collected in Step 3 
• 2 µL of calcofluor white stain 
• 2 µL of potassium hydroxide solution.  
Add a cover slide, making sure to avoid air bubbles. 
5. Visualize the yeast on a confocal microscope using a 63x objective lens. The 
microscope should be equipped with both a 488 and a 405 nm laser lines to excited 
GFP and calcofluor white, respectively.   
iii. GPCR Luminescence Assay 
1. Start an overnight culture of 5-HTR4b-sensing strain by taking a small loopful of the 
patch and inoculating 5 mL of SD(HL-). Shake at 30°C and 250 rpm. [see Note 3]. 
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2. The next day, use the overnight to inoculate 20 mL of SD(H-) to an OD600 = 0.06. 
Incubate the culture at 15°C, 150 rpm for 18 h. 
3. Centrifuge the culture 10 min x 3500 rpm, decant, and resuspend cells in SD(HL-) 
to OD600 = 1. 
4. To a 96 well plate, add:  
• 190 µL of fresh SD(HL-) pH 7 [see Note 4] 
• 8 µL of cell suspension obtained from Step 3 
• 2 µL of chemical or chemical carrier solvent as a control [see Note 5, 6]. A 
chemical carrier solvent control and a serotonin positive control should be 
run in triplicate on the same plate. 
• Cover plate using breathe-easy® membrane [see Note 7]. 
• Incubate for 2 h x 250 rpm at 30 °C   
5. While incubating, allow Promega Nano-Glo® buffer to melt at room temperature. 
Just before the 2 h incubation is over, create a 1:100 dilution of Nano-Glo® 
Substrate: Nano-Glo® Buffer.   
6. Remove breathe-easy® membrane and pipet 20 µL of Nano-Glo® Substrate: 
Nano-Glo® Buffer dilution into each well.  
7. Place a new breathe-easy® membrane and incubate at 30 °C, 250 rpm for 30 min.  
8. Remove breathe-easy® membrane and read immediately on luminescent plate 
reader (i.e. Biotek Synergy 2) [see Note 8] 
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Figure A1.1 – Representative raw data from the 5-HTR4 assay with serotonin. 
iv. Secondary Assay: Dose-response Curves 
If hits are detected in a screen, follow the same protocol using both the 5-HTR4B-
sensing and Control sensing strain and run dose-response curves to confirm luminescence 
signal is GPCR dependent [see Note 9]. Figure A1.1 shows representative data. 
v. Z-score Analysis 
1. Use the equation below to calculate Z-scores from the screen: 
𝒁 − 𝒔𝒄𝒐𝒓𝒆 =
(𝒄𝒉𝒆𝒎𝒊𝒄𝒂𝒍 −𝒎𝒆𝒂𝒏	𝒗𝒆𝒉𝒊𝒄𝒍𝒆	𝒄𝒐𝒏𝒕𝒓𝒐𝒍)
𝑺𝑻𝑫𝒆𝒗	𝒗𝒆𝒉𝒊𝒄𝒍𝒆	𝒄𝒐𝒏𝒕𝒓𝒐𝒍  
2. Normalize the Z-scores to the serotonin positive control by dividing the chemical 
Z-score by serotonin’s Z-score. 
A1.5 Notes 
1. Amount of yeast transformation mixture that is plated may need to be varied to see 
single, well-spaced colonies.  
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2. Colonies should be pink and approximately 2-5 mm in diameter. Smaller white 
colonies are indicative of satellite colonies that will not grow well when patched or 
inoculated overnight.  
3. Overnight OD600s should be ~6-8.   
4. Media is pH to 7 as that is the optimal pH for NanoLuc activity.26  
5. Chemical carrier solvent should be chosen based on chemical solubility. When 
using DMSO, use at less ≤ 1% final concentration. If using other carrier solvents, 
measure the toxicity to yeast to determine maximal final concentration.  
6. The 5-HTR4b assay chemical screen can be run in singlets using all wells in the 
plate. 
7. After placement of breathe-easy® membrane, care should be taken to avoid rough 
handling to prevent cross contamination of wells. Shaking at 250 rpm does not 
cause well cross contamination.  
8. On a Biotek Synergy 2, we use default luminescence gain settings. Testing different 
gains should be done on each machine to ensure optimal signal read out and avoid 
signal saturation.  
9. The Control Sensing strain has higher background than the 5-HTR4b-sensing strain 
at low chemical concentrations. The signal of the 5-HTR4b-sensing strain should be 
higher than the Control Sensing strain with increase in chemical concentration. 
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APPENDIX B. PLASMID TABLES 
Table B.1: Chapter 2 Plasmids 
Number Name Description Source 
PPY111 pKM111 pESC-His3-PTEF1-PADH1 Mukherjee et al. (2015) 
PPY586 pKM586 pRS415- PFIG1-eGFP-Leu2 Mukherjee et al. (2015) 
PPY1658 pHW3 pESC-HIS3-PTEF1-OR2A42- PADH1 This study 
PPY1661 pHW6 pESC-HIS3-PTEF1-OR2W3- PADH1 This study 
PPY1663 pHW7 pESC-HIS3-PTEF1-OR2T4- PADH1 This study 
PPY1715 pHW18 pESC-HIS3-PTEF1-OR51B5- PADH1 This study 
PPY1795 pPB8 pESC-HIS3-PTEF1-OR2L13- PADH1 This study 
PPY1717 pHW20 pESC-HIS3-PTEF1-OR10S1- PADH1 This study 
PPY1718 pHW21 pESC-HIS3-PTEF1-OR2A7- PADH1 This study 
PPY1719 pHW22 pESC-HIS3-PTEF1-OR2A42-GFP This study 
PPY1720 pHW23 pESC-HIS3-PTEF1-OR51B5-GFP This study 
PPY1734 pHW30 pESC-HIS3-PTEF1-OR2T4-GFP This study 
PPY1737 pHW33 pESC-HIS3-PTEF1-OR2W3-GFP This study 
PPY1947 pPB59 pESC-HIS3-PTEF1- OR2A7-GFP This study 
PPY1948 pPB60 pESC-HIS3-PTEF1-OR10S1-GFP This study 
PPY1930 pPB54 pESC-HIS3-PTEF1-OR2L13-GFP This study 




Name Description Citation 
PPY111 pKM111 pESC-His3-pTEF1-tCYC1 Mukherjee et al. 2015 
PPY586 pKM586 pRS415-Leu2-pFIG1-GFP Mukherjee et al. 2015 
PPY1192 pTMC18 pESC-His3-pTEF1-HTR4 Ehrenworth et al. 2017 




APPENDIX C. PRIMER TABLES 



























Table C.2: Chapter 3 Primer 







APPENDIX D. STRAIN TABLES 
Table D.1: Chapter 2 Strains 
Strain Number Description Source 
PPY140 S. cerevisiae MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3 
leu2-112 can1-100 Δfar1, Δsst2, Δste2 
Mukherjee et al. 
(2015) 
PPY1800 PPY140 carrying pKM111 and pKM586 This study  
PPY1801 PPY140 carrying pHW3 and pKM586 This study 
PPY1802 PPY140 carrying pHW6 and pKM586 This study 
PPY1803 PPY140 carrying pHW7 and pKM586 This study 
PPY1804 PPY140 carrying pHW18 and pKM586 This study 
PPY1805 PPY140 carrying pPB8 and pKM586 This study 
PPY1806 PPY140 carrying pHW20 and pKM586 This study 
PPY1807 PPY140 carrying pHW21 and pKM586 This study 
PPY1949 PPY140 carrying pHW22 This study 
PPY1950 PPY140 carrying pHW23 This study 
PPY1951 PPY140 carrying pHW30 This study 
PPY1952 PPY140 carrying pHW33 This study 
PPY1953 PPY140 carrying pPB59 This study 
PPY1954 PPY140 carrying pPB60 This study 
PPY1955 PPY140 carrying pPB54 This study 
Table D.2: Chapter 3 Strains 
Strain 
Number Description Citation 
PPY140 S. cerevisiae W303 MATa ade2-1 ura3-1 his3-11 trp1-1 leu2-3 leu2-112 can1-100 Δfar1 Δste2 Δsst2  Mukherjee et al. 2015 
PPY1808 PPY140 carrying pTMC18 and pEY15 This study 




APPENDIX E. PRINCIPAL COMPONENT ANALYSIS TABLES 
AND FIGURE 
Table E.1: Chapter 2 Abbreviations and chemical descriptors for PCA analysis 
Descriptors Abbreviations 
Molecular Weight MW 
Carbon atom count CAC 
Hydrogen atom count HAC 
Oxygen atom count OAC 
Nitrogen atom count NAC 
Hydrogen-bond donors HBD 
Hydrogen-bond acceptor HBA 
Rotatable bonds RB 
Stereocenter count SC 
Topological polar surface area TPSA 
Number of rings NOR 
Aromatic ring count ARC 
Ring system count RSC 
Size of largest ring SLR 













Table E.2: Chapter 2 Chemical space coordinates of the screened chemicals 











1 - - - 9 15.8 
2 + - - 8 14.0 
3 - - + 6 10.5 
4 + - + 8 14.0 
5 + + - 2 3.5 
6 - + - 13 22.8 
7 + + + 6 10.5 
8 - + + 5 8.8  
Total: 57 100 
Figure E.1: Chapter 2 Eigenvalues for principal component determination 
 
Figure E.1 – Two criteria to be considered in determining number of principal 
components are: 1) number of PCs with eigenvalues greater than one (red dashes 
and red arrows), 2) PCs located after bends or knees (blue dashes and blue arrow). 
Solo analysis resulted in six eigenvalues greater than one, thus six PCs (PCs 1 to 6) 
could be considered for the analysis. Two bends were also observed on the graph at 
PC2 and PC4, meaning that the PCs after the bends (PC3 and PC5) need to be 
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APPENDIX F. CHEMICAL PANEL TABLES 
Table F.1: Chapter 2 Table of chemicals in the chemical panel 
Table F.1 Table of chemicals in the chemical panel 
Chemical CAS # Supplier Catalog # 
(-)-limonene 5989-54-8 TCI Chemicals L0132 
(+)-carvone 6485-40-1 TCI Chemicals C0703 
(+)-menthol 2216-51-5 TCI Chemicals M0826 
1,2,3-trimethylbenzene 526-73-8 TCI Chemicals T0468 
1-butanol 71-36-3 TCI Chemicals B0944 
1-butoxy-2-propanol 5131-66-8 TCI Chemicals B0864 
1-dodecanol 112-53-8 Alfa Aesar A12228 
1-octanol 111-87-5 TCI Chemicals O0036 
1-propanol 71-23-8 TCI Chemicals P0491 
2,3-heptadione 96-04-8 TCI Chemicals H0422 
2,5-dimethylpyrazine 123-32-0 TCI Chemicals D1526 
2-methyl-1-butanol 137-32-6 TCI Chemicals M0175 
3-hexanone 589-38-8 TCI Chemicals H0115 
3-pentanol 584-02-1 TCI Chemicals P0057 
acetic acid 64-19-7 VWR BDH3092 
alpha-pinene 80-56-8 Sigma-Aldrich 305715 
anisaldehyde 123-11-5 TCI Chemicals A1674 
beta-pinene 127-91-3 Sigma-Aldrich CRM40433 
butyric acid 107-92-6 TCI Chemicals B0754 
coumarin 91-64-5 TCI Chemicals C0395 
ethyl decanoate 110-38-3 TCI Chemicals D0022 
ethyl laurate 106-33-2 TCI Chemicals L0013 
ethyl myristate 124-06-1 TCI Chemicals M0479 
ethyl octanoate 106-32-1 TCI Chemicals O0030 
ethyl palmitate 628-97-7 Alfa Aesar A15694 
ethyl stearate 111-61-5 TCI Chemicals S0079 
 108 
eugenol 97-53-0 Alfa Aesar A14332 
farnesol 4602-84-0 TCI Chemicals T0608 
geraniol 106-24-1 TCI Chemicals G0027 
heptanoic acid 111-14-8 Alfa Aesar A17704 
hexanoic acid 142-62-1 Alfa Aesar A13789 
isovaleric acid 503-74-2 TCI Chemicals M0182 
lactic acid 50-21-5 Alfa Aesar 36415 
lauric acid 143-07-7 TCI Chemicals L0011 
lilial 80-54-6 TCI Chemicals B1145 
linalool 78-70-6 TCI Chemicals L0048 
lyral 31906-04-4 Sigma-Aldrich 95594 
melatonin 73-31-4 Sigma-Aldrich M5250 
methyl decanoate 110-42-9 Alfa Aesar A15658 
methyl laurate 111-82-0 Alfa Aesar A12492 
methyl myristate 124-10-7 Alfa Aesar A10257 
methyl octanoate 111-11-5 Alfa Aesar A10991 
methyl palmitate 112-39-0 TCI Chemicals S0311 
methyl stearate 112-61-8 TCI Chemicals S0312 
m-xylene 108-38-3 Sigma-Aldrich 95670 
myristic acid 544-63-8 TCI Chemicals M0476 
nonanal 124-19-6 TCI Chemicals N0296 
octanal 124-13-0 Alfa Aesar A10901 
octanoic acid 124-07-2 Alfa Aesar A11149 
palmitic acid 57-10-3 TCI Chemicals P0002 
p-cymene 99-87-6 TCI Chemicals C0513 
pentadecanoic acid 1002-84-2 Alfa Aesar A14664 
propionic acid 79-09-4 TCI Chemicals P05000 
sotolon 28664-35-9 TCI Chemicals D1851 
stearic acid 57-11-4 TCI Chemicals S0163 
undecanal 112-44-7 TCI Chemicals U0009 




APPENDIX G. DNA SEQUENCES 
G.1: Chapter 2 Sequences 













































































































































G.2: Chapter 3 Sequence 
G.2.1 Yeast-optimized NanoLuc sequence   
ATGGTCTTCACCTTGGAAGATTTCGTCGGTGATTGGAGACAAACCGCTGGTTA
CAACTTGGATCAAGTCTTAGAGCAGGGTGGAGTCTCCTCCTTGTTTCAAAACT
TGGGAGTCTCCGTCACCCCAATTCAAAGAATTGTTTTGTCCGGTGAAAATGGT
TTGAAAATTGATATTCATGTCATTATTCCTTACGAAGGTTTGTCCGGTGATCA
AATGGGTCAAATTGAAAAGATTTTCAAGGTCGTCTACCCAGTTGATGATCATC
ATTTTAAAGTCATTTTGCATTACGGTACCTTGGTCATTGATGGTGTCACCCCA
AACATGATTGATTACTTTGGTAGACCTTACGAAGGTATTGCTGTCTTTGATGG
TAAGAAGATTACCGTTACTGGTACCTTGTGGAATGGTAACAAGATTATTGAT
GAAAGATTGATTAACCCAGATGGTTCCTTGTTGTTTAGAGTCACTATTAATGG
TGTCACTGGTTGGAGATTGTGTGAAAGAATTTTGGCTTAA 
 
 
 
